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Abstract 
Ongoing research is unveiling the role of glial cells in the development of neurological diseases. 
However, it is yet unclear whether mitochondrial dysfunction or altered mitochondrial dynam-
ics can trigger astrocytic death or secondarily affect neuronal function. The mitochondrial m-
AAA protease is essential for neuronal survival. Mutations in its subunits AFG3L2 and para-
plegin lead to the development of different neurodegenerative diseases, spinocerebellar ataxia 
28 (SCA28) and hereditary spastic paraplegia (HSP) respectively, which strongly affect pa-
tients’ motility. Glutamate excitotoxicity may be a contributor to the neurodegeneration, and 
increasing glutamate uptake by astrocytes ameliorates the phenotype caused by m-AAA prote-
ase dysfunction in a Afg3l2-deficient mouse model of SCA28. In order to dissect the contribu-
tion of astrocytes to the development of the neuronal death, I used two different murine models 
of m-AAA dysfunction. In my thesis, I show that deletion of Afg3l2 in astrocytes (astro-L2 KO) 
leads to the demise of the highly targeted Bergmann glia, radial cells in the cerebellar cortex, 
accompanied with a mild, late-onset motor impairment. When I ablated the m-AAA protease in 
astrocytes by eliminating both Afg3l2 and its murine-expressed homologue Afg3l1 (astro-
DKO), the animals show a very strong and early-onset ataxic phenotype, characterized by in-
duction of mitochondrial stress response, Bergmann glia loss, reactive astrogliosis and inflam-
mation. EAAT1 and EAAT2 glutamate transporters are strongly reduced in cerebella of astro-
DKO, and glutamate levels are also reduced. Furthermore, necroptotic markers are upregulated 
and Purkinje neurons, the biggest neurons in the cerebellum that are strongly affected in SCA28, 
show morphological and electrophysiological alterations, revealing a secondary neuronal dys-
function. I propose that the m-AAA protease dysfunction in astrocytes leads to glutamate exci-
totoxicity and inflammation that worsen the already dysfunctional neurons in patients carrying 
mutations in AFG3L2.	
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Zusammenfassung  
Die Rolle von Gliazellen bei der Entwicklung von neurologischen Erkrankungen ist der Fokus 
vieler laufender Studien. Es ist jedoch noch unklar, ob mitochondriale Dysfunktion oder 
veränderte mitochondriale Dynamik den Tod der Astrozyten auslösen oder sekundär die 
neuronale Funktion beeinflussen können. Die mitochondriale m-AAA-Protease ist essentiell für 
das neuronale Überleben. Mutationen in den Untereinheiten AFG3L2 oder Paraplegin führen 
zur Entwicklung verschiedener neurodegenerativer Erkrankungen, der spinozerebellären 
Ataxie 28 (SCA28) und der hereditären spastischen Paraplegie (HSP), die die Beweglichkeit 
der Patienten stark beeinflussen. Glutamat-Exzitotoxizität kann zur Neurodegeneration 
beitragen und eine erhöhte Glutamataufnahme durch Astrozyten verbessert den durch m-AAA-
Proteasedysfunktion in einem Afg3l2-defizienten Mausmodell von SCA28 verursachten 
Phänotyp. Um den Beitrag von Astrozyten zur Entwicklung des neuronalen Todes zu 
analysieren, verwendete ich zwei verschiedene murine Modelle der m-AAA-Dysfunktion. In 
meiner Dissertation zeige ich, dass die Deletion von Afg3l2 in Astrozyten (Astro-L2 KO) zum 
Absterben der hochgradig zielgerichteten Bergmann-Gliazellen im Kleinhirnkortex führt, 
begleitet von einer milden, spät einsetzenden Motorschädigung. Wenn ich die m-AAA-Protease 
in Astrozyten eliminiere, indem ich sowohl Afg3l2 als auch sein nur in der Maus exprimiertes 
Homolog Afg3l1 (Astro-DKO) ausknocke, zeigten die Tiere einen sehr starken und früh 
einsetzenden ataxischen Phänotyp, gekennzeichnet durch Induktion der mitochondrialen 
Stressreaktion, dem Verlust von Bergmann Glia, Zellen, reaktiver Astrogliosis und 
Entzündung. EAAT1 und EAAT2 Glutamat-Transporter sind im Kleinhirn von Astro-DKO-
Mäusen stark reduziert, und der Glutamat-Spiegel ist ebenfalls reduziert. Darüber hinaus sind 
nekrotische Marker hochreguliert und Purkinje Neuronen, die größten Neuronen im Kleinhirn, 
die in SCA28 stark betroffen sind, zeigen morphologische und elektrophysiologische 
Veränderungen, die eine sekundäre neuronale Dysfunktion zeigen. Ich postuliere, dass die m-
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AAA-Protease-Dysfunktion in Astrozyten zu Glutamat-Exzitotoxizität und Entzündung führt, 
die die bereits dysfunktionalen Neuronen bei Patienten, die Mutationen in AFG3L2 tragen, 
zusätzlich verschlechtern.	
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1 INTRODUCTION 
1.1 Astrocytes 
The central nervous system (CNS) includes several cell types, beside neurons. These other cells 
are commonly called glia or glial cells, and consist of astrocytes, oligodendrocytes, microglia 
and ependymal cells [1]. Astrocytes are considered the most abundant glial type, and are in 
charge of different functions within the CNS, such as maintaining brain homeostasis, providing 
metabolic support to neurons, supporting synapse formation and plasticity, regulating ion 
balance, uptaking and recycling neurotransmitters [2]. Collectively known as astroglia, 
astrocytes are quite heterogeneous: they have been classified depending on the morphology, 
developmental features, proliferative capability and factors controlling their proliferation, ion 
channels, electrophysiological properties, gap junctions, specific proteins and RNA, activation 
after injury [3]. 
Astrocytes are usually categorized morphologically and localization-wise in protoplasmic and 
fibrous. Protoplasmic astrocytes are located in the gray matter, have ovoid somata that give rise 
to several branches, whereas fibrous astrocytes are found in the white matter and have several 
fiber-like processes. While processes of protoplasmic astrocytes envelop synaptic buttons, 
fibrous astrocytes are in intimate contact with the nodes of Ranvier. Many more types of 
astroglial cells have been described, such as Bergman glia, Müller cells of the retina, 
perivascular astrocytes and radial astrocytes [4]. Astrocytes are organized in domains, which 
are distinct and non-overlapping. The first evidence came from a study on hippocampal 
astrocytes [5, 6], but other studies confirmed the same organization in rodents cortex [7-9]. The 
functional role of the domains is not clear yet, but these domains are quite extensive: one single 
astrocyte can enwrap 140,000 synapses in the hippocampus, as well as regulating the blood 
flow in the area by being in contact with the blood vessels [5]. 
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Astrocytes are histochemically identified using antibodies against the glial fibrillary acidic 
protein (GFAP), which is a protein of the intermediate filaments, highly expressed in this cell 
type [10, 11]. However, GFAP is not always histochemically detectable in astrocytes in healthy 
conditions. In fact, studies with several markers for astrocytes demonstrated that many 
astrocytes show variability in the GFAP expression level, which is regulated by intracellular 
and extracellular stimuli [2]. Nevertheless, GFAP is a reliable marker for reactive astrocytes. 
In fact, in case of tissue injury, infection and neurodegenerative diseases, the extracellular space 
is flooded with chemokines, cytokines and debris. When triggered by these stimuli, astrocytes 
increase in size, upregulate GFAP and induce molecular, cellular and functional changes aimed 
to limit the tissue damage, or provide aid for tissue repair [2, 12]. 
1.1.1 Astrocytic functions 
Glial cells were considered to be the glue connecting the neurons in the CNS, but it has become 
clear that this definition does not reflect the reality of the complexity, or the functional 
properties of glial cells [13]. Indeed, astrocytes are pleiotropic cells, which exert different 
functions aimed to maintain CNS homeostatic equilibrium and sustain neuronal function. 
1.1.1.1 Synaptic function 
As they enwrap the synapses, astrocytes have a stringent contact with pre and postsynaptic 
entities. The environmental control of the synaptic cleft must be tightly regulated to avoid 
hyper-stimulation of the postsynaptic neuron. Astrocytes express on their surface both GABA 
transporters (GATs) [14] and excitatory amino acids transporters (EAATs) [15], and are 
involved in their recycling to replenish neuronal pools [16]. As for their role in synaptic 
regulation, the former bipartite synapse is now accepted as a tripartite synapse [17-19]. They 
have potassium and sodium channels, and calcium fluctuations that can elicit inward currents, 
but differently from neurons, as astrocytes do not propagate action potentials [20, 21]. Despite 
Introduction 
 
6 
 
that, the astrocytic inward currents can induce release of neuroactive substances such as purines 
and neurotransmitters (GABA and glutamate), therefore affecting neuronal activity [18-20, 22]. 
Moreover, astrocytes influence the synapses by releasing also neuroactive steroids (estradiol 
and progesterone) and metabolites that influence the postsynaptic button [23]. In addition, 
synapse formation is highly regulated by astrocytes during development: they guide axons 
during their elongation phase by releasing thrombospondin and other signaling molecules [24-
26].  
1.1.1.2 Regulation of blood flow and fluid homeostasis 
Astrocytes physically contact blood vessels with their processes, and can regulate the blood 
flow in the CNS via the release of prostaglandins, nitric oxide and arachidonic acid. These 
mediators are known to regulate vessel diameter and blood flow [27]. Considering that 
astrocytes are tightly communicating with neurons, they could be able to regulate blood flow 
depending on neuronal activity. In fact, it was shown that blood flow changes in response to 
visual stimuli in the visual cortex, and the changes are mediated by astrocytic activity [28]. 
Moreover, astrocytic processes express clustered aquaporin 4 water channels (AQP4), which 
are involved in regulation of water influx. It was shown, in fact, that AQP4 knockout animals 
have an increased extracellular space volume (+25%) and increased water content compared to 
control animals [29-31]. AQP4 function is critical in the first postnatal days, when water volume 
in the brain is reduced up to 80%. Furthermore, several studies tried to understand the role of 
AQP4 in management of edema and stroke, but conflicting results, mainly obtained using 
transgenic animals, did not allow to uncover fully the implication of AQP4 in brain trauma [32]. 
1.1.1.3 Energy support 
Astrocytes are considered glycolytic cells and even if oxidative phosphorylation (OXPHOS) is 
still used for adenosine triphosphate (ATP) production, it is not the main energy production 
pathway for the cells [33, 34]. In fact, glycolytic genes expression is increased in these cells 
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[33, 35] and especially they highly express the 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase isoform 3 (PFKFB3), a glycolysis inducer enzyme. This enzyme is subjected to 
continuous degradation via the proteasome in neurons [36], imposing their requirement for ATP 
production via OXPHOS. Several studies proposed that astrocytes support neuronal function 
by performing aerobic glycolysis and providing neurons with lactate. When glutamate is 
released as neurotransmitter from the presynaptic entity, it activates glutamate receptors in 
neurons. To avoid excitotoxicity, astrocytes express the amino acids transporters 1 and 2 
(EAAT1 and 2) to uptake glutamate from the synaptic cleft. To this purpose, the 
electrochemical gradient of Na+, which is maintained by Na+/K+ ATPase is used as driving 
force [37]. Once in astrocytes, glutamate is converted to glutamine by the glutamine synthase 
and shuttled back to the neurons to be converted to glutamate and replenish the vesicles. Both 
glutamate signaling in neurons and glutamate uptake in astrocytes are energy-requiring 
processes. Therefore, the energetic status has to be high. To provide both astrocytes and neurons 
with enough ATP, glucose coming from the bloodstream is converted to pyruvate via glycolysis 
in astrocytes. To maintain the flux, NADH is oxidized to NAD+ through the conversion of 
pyruvate in lactate. This is then released in the extracellular space via the monocarboxylate 
transporter 1 (MCT1). Once in the extracellular space, lactate is transported into neurons via 
the MCT2, where it is converted to pyruvate by the lactate dehydrogenase 1 and used as 
oxidative substrate for ATP production. This process is known as astrocyte-neuron lactate 
shuttle (ANLS) [38-45]. Despite being widely accepted, ANLS concept was formulated 
following experiments developed in cell cultures. In vivo experiments have given conflicting 
results. In fact two independent studies have shown increased glucose uptake following 
neuronal stimulation in astrocytes [46] or neurons [47]. Moreover, Diaz-Garcia et al., show that, 
using metabolic biosensors, in both acute hippocampal slices and in brains of awaken mice, 
synaptically stimulated cytosolic NADH transients appear in neurons rather than in astrocytes. 
This was independent from astrocytes stimulation via glutamate and lactate import in neurons, 
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whereas NADH transients in neurons reflect increased neuronal glycolysis. In fact, by using the 
irreversible glycolysis blocker, iodoacetic acid, no transients were observed. The authors 
propose that ANLS can occur in resting phase, but not during neuronal stimulation [48]. 
1.1.1.4 Reactive astrogliosis 
Astrocytes monitor neuronal activity and function. Following stroke, CNS trauma or 
neurodegenerative diseases, they are in charge of limiting the damage and restore CNS 
functionality. To fulfill their duty upon damage, astrocytes enter a state called reactive 
astrogliosis. Mild reactive astrogliosis consists of cell body hypertrophy and changes in gene 
expression, but cells maintain their domain distinction. A mild reactive state occurs in case of 
not severe trauma, viral and bacterial infections that activate the immune system, and is also 
observed in areas surrounding a lesion in the CNS [2, 4, 49]. Severe reactive astrogliosis is 
characterized additionally by loss of domain organization and proliferation. It manifests in case 
of ischemia, severe trauma and neurodegeneration [2, 4]. Reactive astrogliosis leads to the 
formation of the so called “astroglial scar”, which consists of newly proliferated astrocytes 
closely packed, with their processes intimately entangled creating a compact border for the 
affected area [50, 51]. The lesion core contains several types of cells, including astrocytes, 
fibroblasts, fibrocytes, pericytes and microglial cells. Moreover, the core collagenous 
extracellular matrix is enriched with astroglia derived proteoglycans that inhibit axonal growth 
[52].  
Reactive astrocytes function does not end with the formation of the glial scar though. In fact, 
they are responsible for secretion of neurotrophins, clearance of dead cells and debris as well 
as phagocytosis of synapses and repair of the brain-blood-barrier [12, 53-56]. Another 
important feature of reactive astrocytes is their interaction and interplay with the resident 
immune cells of the CNS, called microglia. In fact, microglia and reactive astrocytes can recruit 
each other to the damaged area and actively interact to limit the tissue damage and promote 
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repair [57, 58]. It was indeed shown that in case of traumatic brain injury, ischemia, neuropathic 
pain and more, microglia is the first responder in the core of the injury, and release cytokines, 
such as interleukin-1 β (IL-1β), tumor necrosis factor α (TNF-α), and interferon γ. They recruit 
reactive astrocytes, and downregulate the purinergic receptor P2Y1 on astrocytes surface, 
promoting neuroprotection [58]. Moreover, it was also shown that in a model of chronic 
experimental autoimmune encephalomyelitis (a model of multiple sclerosis) activated 
astrocytes increase the release the chemokine C-C motif ligand 2 and 4 (CCL2 and CCL4), 
which induce activation of microglia [59-62]. 
It should be noted that astrocytes have at least two different activation states. 
Neuroinflammation produces A1 reactive astrocytes, while ischemia induces A2 reactive 
astrocytes [4, 12, 63]. A1 astrocytes are considered harmful for the neurons, as they promote 
release of soluble toxins that kill different types of neurons , as well as mature oligodendrocytes, 
and upregulate the nuclear factor kappa light chain reaction (NFκB) [55, 63]. A2 astrocytes are 
instead considered helpful in case of ischemia, as they promote STAT3-mediated proliferation 
and scar formation, and in absence of STA3 in astrocytes, there is extensive axonal degeneration 
following spinal cord injury.[12, 55, 63]. Therefore, reactive astrogliosis in not a unique and 
uniform state that activated astrocytes undergo in case of injury, but a complex remodeling of 
astrocyte gene expression and pathway activation aimed to overcome injuries in a selective 
way, limiting tissue damage or destroying the cause. 
1.1.2 Astrocytes involvement in neurodegeneration 
Due to their pleiotropic functions during development and maintenance of the CNS, it is not 
surprising that astrocytes play a key role in neurodegeneration. One of the questions that 
researchers in the field are trying to answer to is whether during neurodegeneration astrocytes 
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become unable to support neurons (loss-of-function) or if they upregulate pathways that make 
them toxic (gain-of-function) [64].  
As astrocytes are necessary for neuronal survival [65], loss of their function could be a trigger 
of neurodegeneration. For example, Alexander disease is an autosomal dominant disease caused 
by mutations in GFAP. It is a leukodystrophy triggered by accumulation of mutated GFAP, 
heat shock protein 27, and αβ-crystalline aggregates called Rosenthal fibers. With time, the 
aggregates become bigger and cause morphological changes such as reduction of fine processes 
number, enlarged body and nucleus, which could be due to misalignment of chromosomes 
during mitosis caused by the Rosenthal fibers [66, 67]. The disease progression causes 
abnormal myelination, maybe because oligodendrocytes precursors express GFAP [68], and 
glia-induced nitric oxide release, which causes neurodegeneration [69]. Another 
neurodegenerative disease caused by astrocytes dysfunction is the hepatic encephalopathy. It 
occurs in cases of cirrhosis and it is a consequence of toxic metabolites coming from impaired 
liver activity. Particularly ammonia, once reaches the brain through the bloodstream, is 
detoxified by astrocytes. It results in the excessive production of glutamine, which causes 
osmotic swelling of the cells. As a response, astrocytes alter the expression of key glutamate 
transporters and water channels in the attempt to compensate for the swelling. However, by 
doing this, their function of properly monitor neuronal activity is inhibited and their ability to 
maintain CNS homeostasis is reduced, leading to the development of a neuropsychiatric 
syndrome [64, 70]. 
In addition to diseases caused by primarily astrocyte-specific protein mutations or loss of 
function caused by toxic metabolites, astrocytes relevance was also demonstrated in neuronal-
focused diseases. Accumulation of amyloid-β plagues have been found in astrocytes in post-
mortem Alzheimer disease brains [71-73]. Wild-type astrocytes internalize amyloid-β when 
transplanted in Alzheimer disease mouse model brains [74, 75]. It was also shown that 
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astrocytes connectivity is impaired [76, 77], and the blockade of hemichannels forming gap-
junctions between astrocytes ameliorates memory-related phenotypes without affecting plagues 
inside the cells [78]. Astrocytes expressing mutated huntingtin, which causes the 
neurodegenerative disorder Huntington disease, have been found to be toxic for wild-type 
neurons in co-culture [79], and appear to have reduced expression of Kir4.1 channels [80]. This 
results in reduced potassium-buffering capability. Moreover, astrocyte-specific mutation of 
huntingtin protein is sufficient to cause neurodegeneration [81, 82]. In Parkinson disease, 
astrocytes uptake α-synuclein released from axons [83, 84]. These aggregates lead to production 
of proinflammatory cytokines and chemokines, and when a mutated α-synuclein was 
specifically expressed in astrocytes, it led to non-cell autonomous neurodegeneration resulting 
in paralysis [83]. The aggregates have the capability of impairing glutamate uptake by 
astrocytes, as well as impairing their ability to regulate the blood-brain barrier [85]. In the case 
of inherited amyotrophic lateral sclerosis, mouse models in which the mutation occurs only in 
motor neurons do not show the canonical disease [86-88]. Moreover, chimeric mouse models 
show that mutated glial cells can damage wild-type neurons, whereas healthy wild-type glial 
cells can delay the phenotype progression in mutated neurons [89]. Evidences of astrocytes 
involvement in brain tumors, epilepsy, major depressive disorder have also been gathered [90], 
further sustaining the hypothesis that neurological diseases and neurodegenerative disorders go 
beyond neuronal dysfunction as more than one player is indeed involved. 
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1.2 Mitochondria 
Mitochondria are essential organelles for eukaryotic cells. According to the endosymbiotic 
theory postulated by Wallis [91], mitochondria are descendant of α-proteobacteria that were 
included into a not yet clarified host. Despite the initial resistance to the theory, nowadays it is 
well accepted, and more studies were conducted to find out which type of bacteria gave rise to 
mitochondria and which type of cell was the host. Moreover, heated discussion is currently 
ongoing, as the timing of mitochondria acquisition and development of the eukaryotic cells is 
controversial: many believe that mitochondrial incorporation inside the cell was the first step 
towards the eukaryogenesis, others claim that it was the last one [92]. To add another shadow 
to the endosymbiosis theory and the eukaryotic evolution, Karnokowska et al., [93] describe 
the oxymonad Monocernocomonoides as an microbial eukaryotic organism that has standard 
eukaryotic features, but lacks mitochondria. The authors do not deny that mitochondria were 
present during the evolution of this organism, but were lost overtime, implying that 
mitochondria cannot and should not be considered indispensable components of eukaryotic 
cells. 
The inheritance from mitochondrial bacterial ancestors is the double membrane surrounding 
the organelle, and its own DNA. The outer and inner mitochondrial membranes (OMM and 
IMM) are composed of phospholipids; the space between them is called intermembrane space 
(IMS). The IMM creates invagination, called cristae, protruding in the core of the 
mitochondrion, called matrix [94]. The cristae morphology is maintained by the mitochondrial 
contact site and cristae organizing system (MICOS), and the optic atrophy protein 1 (OPA1) 
[95-97]. Mitochondrial DNA (mtDNA) is circular; double stranded and has a 16 kbp size. In 
humans, it encodes for 13 proteins, which are part of the OXPHOS complexes, translated by 
the mitochondrial translational machinery. All the other mitochondrial proteins are encoded by 
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the nuclear DNA, as most of the genes present in the original α-proteobacterium were 
transferred to the nuclear genome [98]. 
1.2.1 Mitochondrial functions 
Mitochondria are dynamic organelles in charge of respiration and ATP production, calcium 
buffering and cell death regulation. In the CNS, these organelles are of high importance, as the 
brain consumes 20% of the body´s energy production [45]. 
ATP production starts from different energy sources entering the tricarboxylic acid cycle (TCA) 
as acetyl-coenzyme A: glucose and/or lactate conversion in pyruvate, fatty acids β-oxydation, 
and amino acids deamination. The result of the TCA cycle, among the rest, is the production of 
the reduced carriers NADH and FADH2 that are electron donors for the OXPHOS, operated by 
the electron transport chain. It consists of four complexes, which remove electrons from the 
electron donors and create a proton gradient by pumping protons H+ in the IMS. The fifth 
complex, called ATP synthase generates ATP using the proton gradient generated by the 
electron transport chain. This series of reactions is very profitable in terms of energy production, 
with an ATP yield of 30-36 molecules per glucose molecule [45]. 
Ca2+ buffering is of relevance for the CNS, as its imbalance can cause hyper-stimulation and 
death of the cells. Mainly, mitochondrial Ca2+ uptake is mediated by the mitochondrial calcium 
uniporter (MCU) complex. It is located in the IMM and has low Ca2+ affinity. Therefore, it 
requires high concentrations of cytosolic Ca²+ to open. The low affinity of the uniporter to Ca2+ 
is guaranteed by its gatekeeper component, the mitochondrial calcium uniporter protein 
(MICU), which senses the ion concentrations and induces the morphological changes leading 
to the opening of the MCU complex at high cytosolic Ca2+ concentrations [99]. Calcium efflux 
from mitochondria is operated via the Na+/Ca2+/Li+ exchanger (NCLX) and the mitochondrial 
permeability transition pore (MPTP). Na+ concentrations are higher in the cytosol than in the 
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matrix, and mitochondrial membrane potential is around -150 to -180 mV. These two conditions 
generate a strong driving force that activates the NCLX, which transports 3 Na+ inside 
mitochondria and release out 1 Ca2+. The MPTP on the other end is an IMM channel that opens 
when mitochondria undergo Ca2+ overload. Its prolonged opening causes IMM potential 
collapse, blockade of ATP production, mitochondrial cristae swelling and rupture that leads to 
cell death [100].  
Mitochondrial calcium has an effect on mitochondrial ATP production, as it activates 3 different 
mitochondrial  dehydrogenases, increasing NADH production, and it also induces the activity 
of the ATP synthase [101]. In neurodegenerative diseases, different neuronal populations show 
higher sensitivity to specific mutations. Understanding what determines this higher 
susceptibility to cell death is crucial. For some diseases it seems that mitochondrial calcium 
buffering (and generally, calcium homeostasis) makes specific neuronal populations more 
susceptible to cell damage and death [102]. In fact, calcium homeostasis is primarily modulated 
in neurons through voltage or ligand-gated ion channels, and secondarily by intracellular 
signaling. In glial cells, Ca2+ is mainly released by the endoplasmic reticulum (ER) via inositol-
3 phosphate signaling. In neurons, calcium is buffered by mitochondria and induces TCA cycle 
when stored in the matrix, increases ATP production and the activity of the aspartate carrier 
[103]. Moreover, mitochondrial buffering activity is strong enough to modulate the propagation 
of synaptic signal in neurons, as well as modulate intercommunication among astrocytes [102, 
104]. Changes in Ca2+ concentrations in mitochondria can also induce cell death, by opening 
the MPTP and resulting release of pro-apoptotic factors [105]. 
Cell death can occur in case of cellular dysfunction or external insult. It can be 
modulated/programmed (apoptosis and necroptosis) or disorganized (necrosis). Mitochondria 
are involved in both cell death pathways in different ways. Apoptosis is triggered by different 
signals, such as extracellular ligands that induce the formation of the death-inducing signaling 
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complex (DISC): this complex drives caspase activation cascade that modulates the elimination 
of the cell. The activation of caspase 8 via the DISC complex leads to the release cytochrome  
c from mitochondria, amplifying the apoptotic response [106]. Other activators of apoptosis are 
the intrinsic signal of mitochondrial damage, intracellular calcium overload and oxidative 
stress. These signals induce the opening of the MPTP, which causes the release of pro-apoptotic 
factors, such as cytochrome c, inducing the caspases activation cascade [105, 107]. Opposite to 
apoptosis, necrosis is characterized by mitochondrial swelling, impaired ATP production and, 
despite the release of pro-apoptotic stimuli form mitochondria, blockade of apoptosis due to 
ATP insufficiency [105]. Necrosis results in the breakage of cell membrane and release of the 
cell content in the extracellular space [108]. A regulated form of necrosis is the one induced by 
activation of the receptor-interacting protein family of serine/threonine protein kinases (RIPK), 
called necroptosis. This death pathway is dependent on mitochondrial production of reactive 
oxygen species, but not on the opening of the MPTP [109]. 
1.2.2 Mitochondrial quality control 
Mitochondria must be strictly monitored, as their dysfunction can lead to cellular death. 
Therefore, organelle quality control is essential to guarantee cellular functionality and survival. 
The organelle quality control consists of regulation of mitochondrial dynamics (fusion/fission), 
de novo mitochondrial biogenesis and mitophagy [148]. 
During mitochondrial fusion, separated mitochondria fuse together the respective OMM and 
IMM, and the matrix content is mixed. This process is highly regulated by several GTPases: 
mitofusin (Mfn) 1 and 2 control OMM fusion, while OPA1, a dynamin related GTPase, controls 
fusion of the IMM [149]. Mitofusins are located in the OMM and induce mitochondrial fusion 
by homo and hetorotypic interactions and consequent trans-association of the OMMs. 
Moreover, Mfn2 has been reported to be important also for mitochondrial/ ER tethering, even 
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though the dynamics are still debated [150, 151]. The mechanism underlying IMM fusion is 
poorly understood. OPA1 is present in the IMM in different isoforms, called short and long 
OPA1. It has been shown that the IMM bound long OPA1 is required for mitochondrial fusion 
and elongated morphology. Moreover, it was shown that increased long OPA1 cleavage, 
resulting in more short OPA1 isoforms, inhibits fusion and causes mitochondrial fission [152].  
Despite being activated by OPA1 proteolytic cleavage, mitochondrial fission has its own set of 
regulatory elements: the dynamin-related protein 1 (DRP1), the mitochondrial fission protein 1 
(Fis1), the mitochondrial fission factor (Mff) and the mitochondrial dynamics proteins (MiD) 
49 and 51 kDa. Fission occurs at the mitochondria-ER contact sites, where the ER creates 
constrictions around the separation line. DRP1 is a cytoplasmic protein recruited to the OMM. 
It forms oligomers in a ring-like structure that constrict the mitochondria using the hydrolysis 
of GTP at the ER contact site. For this reason, it has been proposed that the ER may have an 
important role in identifying the fission sites [153]. Increased fission has been associated with 
the necessity of eliminating dysfunctional mitochondria, meaning that the dysfunctional part is 
separated and targeted for mitophagy [143]. Increased mitochondrial fragmentation has been 
reported in several neurodegenerative diseases caused by mitochondrial dysfunction, but also 
in diseases caused by mutations in genes not involved in mitochondrial function, such as 
Huntington disease [143]. 
Fragmentation of dysfunctional mitochondria leads to their elimination via mitophagy. It starts 
with the identification of dysfunctional mitochondria via the ubiquitinization of mitochondrial 
surface proteins by E3-ubiquitin ligases. The ubiquitinated substrates recruit adaptors like p62, 
which have an interaction sequence recognized by the microtubule associated protein 1A/1B 
light chain 3 (LC3) located on the autophagosomal membrane. Once the autophagosome is 
formed, it fuses with lysosomes to digest the organelle [154-157].  
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Finally, as old/dysfunctional mitochondria are eliminated, new ones must be generated de novo 
to maintain a functional and healthy mitochondrial network. As mitochondria rely on both the 
nuclear and mtDNA for protein synthesis, mitochondrial protein expression must be 
coordinated within these two components. The peroxisome proliferator-activated receptor-ϒ 
coactivator-1 alpha (PGC-1α) is considered the master regulator of mitochondrial biogenesis, 
as it is a scaffold of different nuclear receptor families and as transcriptional coactivator of 
nuclear respiratory factors (NRFs), peroxisome proliferator-activated receptors (PPAR) and 
more. NRFs are involved in transcription of nuclear-encoded mitochondrial proteins, as well as 
mitochondrial transcription factor A (TFAM), which is in charge of mtDNA transcription and 
replication. 
Protein quality control in mitochondria consists of mitochondrial protein turn over (i.e. protein 
translation and degradation). As mitochondrial proteins are derived from both mitochondrial 
genome and nuclear DNA, the quality control process includes also protein import, proper 
folding and activation. Most mitochondrial proteins are identified by a mitochondrial-targeting 
sequence (MTS) in the N-terminus of the protein, which is usually cleaved upon mitochondrial 
entrance [110, 111]. Before a nuclear-encoded mitochondrial protein enters the organelle, it is 
maintained unfolded in the cytosol by chaperons such as heat-shock proteins (Hsp) 70 and 90 
preventing degradation [112]. To access mitochondria, proteins must be transported through 
the OMM and, in case they are IMM or matrix proteins, they also need to pass through the 
IMM. For these purposes, two translocase complexes exist: the translocase of the OMM (TOM) 
and the translocase of the IMM (TIM). While passing through the TIM complex or once in the 
matrix, unfolded proteins are protected by mitochondrial chaperons (mtHsp) like mtHsp70 and 
Hsp60 [113].  
Mitochondria possess several proteases located in all their compartments, and the mitochondrial 
unfolded protein response (mtUPR) for protein degradation. Mitochondrial proteases exert 
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proteolytic functions and, by cooperating with chaperons, they participate in the import and 
activation of mitochondrial proteins. For example, there are two different AAA (ATPase 
associated with diverse cellular activities) proteases inserted in the IMM: the i-AAA protease 
and the m-AAA protease [114, 115]. The i-AAA protease has its proteolytic site towards the 
IMS, while the m-AAA protease has its own towards the matrix. Together, the mitochondrial 
AAA proteases are involved in the degradation of OXPHOS subunits and to protein activation 
via proteolytic cleavage of newly imported pre-proteins. The AAA proteases activity 
determines also mitochondrial fusion/fission balance. In fact, under metabolic stimulation, the 
i-AAA protease cleaves OPA1, leading to changes in short and long isoforms ratio and inducing 
mitochondrial fission [116, 117]. Furthermore, m-AAA protease dysfunction indirectly 
influences mitochondrial dynamics by inducing the overlapping activity with m-AAA protease 
1 (OMA1)-mediated cleavage of OPA1 and increasing fission events [118] The m-AAA 
protease exert also proteolytic activation functions by cleavage of the N-terminus of the 
mitochondrial ribosomal protein L32 (MRPL32), allowing its proper folding and activation 
[114, 119]. Other proteases are located in the matrix such as the mitochondrial processing 
peptidase (MPP) which is in charge of cleaving off the MTS of the pre-proteins freshly imported 
in mitochondria. Following its activity, other peptidases further process the proteins to either 
stabilize or degrade them [113]. In addition, proteostatic stress can induce the activation of the 
mtUPR, to balance mitochondrial protein homeostasis. In mammals, it was shown that it 
involves upregulation of chaperones and mitochondrial proteases. However, most of the studies 
on mtUPR are conducted in C.elegans. It was shown that a mitochondrial peptidase called Clp 
protease (CLPP) is upregulated in case of mtUPR induction, and generates small peptides that 
are exported out of mitochondria via the HAF-1 transporter to activate transcription factors in 
the nucleus [120, 121].  
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1.3 The m-AAA protease 
1.3.1 m-AAA protease structure  
Maintenance of the mitochondrial proteome is essential for eukaryotic cell survival. 
Mitochondria have a plethora of proteases in charge of protein quality control, located in 
different compartments. The m-AAA protease is a mitochondrial metallopeptidase anchored to 
the IMM. Highly conserved through evolution, it is a hexamer composed of two different 
subunits in humans: AFG3L2 and paraplegin. AFG3L2 can create homooligomeric complexes 
or heterooligomeric complexes together with paraplegin, whereas paraplegin cannot 
homooligomerize [122, 123]. In rodents, a third subunit, highly homologous to AFG3L2 was 
identified and called AFG3L1 [122, 124]. In addition, AFG3L1 is capable of forming both 
homo and heterooligomers (Fig. 1.1). Interestingly, the expression of AFG3L2 and paraplegin 
is higher in mouse brains compared to AFG3L1 (respectively 10 and 4 folds). Moreover, the 
knockout of paraplegin does not change the relative abundance of AFG3l2 over AFG3L1 in 
mouse brains, and AFG3L2 has been shown to be 10 folds more expressed than AFG3L1 also 
in absence of paraplegin [122].  
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Figure 1.1: m-AAA protease composition in humans and mice. Human m-AAA protease is composed 
of two subunits: AFG3L2 and paraplegin. AFG3L2 can homooligomerize or heterooligomerize with 
paraplegin, while paraplegin can only heterooligomerize. In mice, there is another subunit, AFG3L1, 
which can generate homooligomers or heterooligomers. 
Analyses of the yeast homologous of the mammal m-AAA protease subunits, allowed for a 
better understanding of the subunits structure: the protein sequence includes two 
transmembrane domains, an ATPase domain, and a zinc metallopeptidase domain. While the 
matrix-facing N-terminus function is still poorly understood, the coiled-coil at the C-terminus 
seems to be involved in the substrate recognition [125]. The assembly of the hexamer of the 
AAA oligomers is driven by interactions between the ATPase domains, but for the m-AAA 
protease proper assembly, the interaction between the metalloprotease compartments is also 
required [126, 127]. Once assembled, the m-AAA protease comprises a small portion called 
distal domain facing the IMS (Fig. 1.2). Its function is still debated: it could be a simple anchor 
for the protease, or it could be involved in the recognition of substrates [128, 129]. Another 
interesting hypothesis is that the distal domain allows the interaction with m-AAA protease 
regulatory complexes. In all eukaryotic cells, the distal domain of the m-AAA protease interacts 
with the heterodimeric ring formed by prohibitin proteins 1 and 2 (PHB1 and 2) [130]. It has 
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been shown that the prohibitins are negative regulators of the m-AAA protease. In fact, deletion 
of PHB1 or 2 leads to an increased turnover of the m-AAA protease targets, such as the complex 
IV subunit Cox3p in yeasts. In a murine model of PHB2 knockout, it was shown that proteolytic 
cleavage of OPA1 is increased [131, 132].  
 
Figure 1.2: m-AAA protease structure. (A) Schematic representation of the m-AAA protease 
domains: mitochondrial targeting sequence (MTS), transmembrane domain (TM), AAA domain, metal 
binding proteolytic domain (M41), coiled coil (CC). Modified from [133]. (B) Structural localization of 
the m-AAA protease domains. Modified from [134]. 
1.3.2 The m-AAA protease functions 
The m-AAA protease is involved in mitochondrial protein quality control. As protease exerting 
its degradation function, it can completely degrade misassembled, disassembled or damaged 
proteins. The small peptides resulting from this catalytic activity can be exported out of 
mitochondria, or further degraded by other peptidases [115]. The elimination of disassembled 
substrates is extremely important for proper mitochondrial function: accumulation of 
dysfunctional proteins could lead to aggregates formation, morphological alteration of 
mitochondrial structure and increased susceptibility to oxidative stress [134, 135]. It was shown 
that subunits of the respiratory chain and the ATP synthase are targets of the m-AAA protease. 
In fact, Cob subunit of complex III, CoxI and CoxIII of complex IV, and the Su6, 8 and 9 
subunits of the ATP synthase are degraded by the m-AAA protease [132, 136, 137].  
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Another important target of the m-AAA protease is the essential MCU regulator (EMRE). In 
fact, in healthy conditions EMRE binds the mitochondrial calcium uniporter protein (MICU). 
The resulting MICU-EMRE complex creates a cap on the MCU, functioning as gatekeeper for 
calcium entrance in mitochondria. Excessive EMRE, which does not form the MICU-EMRE 
complex, is degraded by the m-AAA protease. In case of m-AAA dysfunction, the excess 
EMRE is not degraded and competes with the assembled MICU-EMRE complex for the 
binding to the MCU. The MICU-EMRE-MCU complex (generally referred to as assembled 
MCU complex) has a low Ca2+ affinity and is mostly closed at low cytosolic Ca2+ concentration. 
On the other hand, the EMRE-MCU, lacking the MICU component, is constitutively active and 
induces Ca2+ overloads in mitochondria, inducing then the MPTP opening and a massive release 
of Ca2+ in the cytosol [138, 139]. This specific substrate bestows on the m-AAA protease an 
indirect regulatory effect on Ca2+ homeostasis.  
Another important function of the m-AAA protease is the proteolytic activation of some of its 
targets. MRPL32 is a component of the mitochondrial ribosome. Opposite to the fate of  EMRE, 
MRPL32 is not completely degraded by the m-AAA protease. In fact, only the N-terminus, that 
in yeast is 71 residues, is cleaved. Once the m-AAA protease encounters the highly stable zinc-
binding domain of the protein, it is unable to process it further and releases it as a mature protein 
of the ribosomal machinery [140]. Moreover, the nuclear encoded cytochrome c peroxidase 
(Ccp) is translocated inside mitochondria following translation in the cytosol. The immature 
form requires two proteolytic processes operated by two different proteases: the m-AAA 
protease processes the premature Ccp between the amino acids in position 36 and 37, whereas 
the rhomboid peptidase processing of cytochrome c peroxidase (Pcp1) cleaves Ccp between the 
amino acids 68 and 69 [141, 142]. Furthermore, it was reported that the m-AAA protease is 
important for the localization of Ccp inside mitochondrial cristae, but weather it occurs for 
diffusion through the cristae opening, or by lateral translocation is not yet clear. It was also 
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shown that the translocation of Ccp is independent of the m-AAA protease proteolytic activity 
[142, 143]. Another suggested target of the m-AAA protease is the long OPA1 [144]. It was 
shown that AFG3L1 and AFG3L2 homooligomeric complexes are able to cleave more 
efficiently long isoforms of OPA1 in short isoforms. However, recent findings revealed that 
OPA1 is cleaved under metabolic stimuli by the i-AAA protease and under stress conditions, 
including m-AAA protease dysfunction, by OMA1. Therefore, the m-AAA protease is 
indirectly involved in mitochondrial fusion/fission balance [116, 118]. Moreover, the m-AAA 
protease is also involved in maturation of OMA1: after mitochondrial import, OMA1 undergoes 
an auto-proteolytic cleavage, but before that it needs to be pre-activated by proteolytic 
processing by the m-AAA protease [117]. Importantly, Koppen et al [145] showed that the m-
AAA protease undergoes an autocatalytic processing. In fact, AFG3L1 and 2 are nuclear 
encoded mitochondrial proteins. Following mitochondrial translocation, AFG3L2 is processed 
by the mitochondrial processing peptidase (MPP), generating an intermediate form of the 
protein. This intermediate undergoes catalytic processing by pre-existing m-AAA protease or 
autocatalytic processing: m-AAA protease depleted cells, in fact, provided with immature 
AFG3L2 are able to induce maturation of only 40% of the protein, suggesting both the necessity 
of pre-existing m-AAA protease and autocatalytic function. Moreover, the same study revealed 
that paraplegin undergoes two proteolytic cleavages as well: the first one by the MPP and the 
second one by pre-existing m-AAA protease. However, it has no autocatalytic activity and 
requires AFG3L2 or AFG3L1 not only for its assembly, but also for its maturation.  
Finally, the m-AAA protease is indirectly involve in mitochondrial protein translation by 
processing MRPL32, a component of the mitochondrial translational machinery. It has also 
been reported that in yeasts that m-AAA protease impairment caused by mutations in the 
proteolytic domain of the protease reduces the transcription of introns-containing mitochondrial 
RNAs of COX1 and Cob [146].  
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Overall, the m-AAA protease function is not limited to proteolytic degradation of its substrates. 
It also comprises maturation and activation of its target proteins (including self-activation), 
translational control of mitochondrial encoded proteins, and translocation of its substrates, 
calcium mitochondrial entrance and mitochondrial fusion/fission balance. 
1.3.3 Neurodegeneration caused by m-AAA protease dysfunction 
Due to its pleiotropic functions, m-AAA protease proper activity is necessary for cellular 
survival , particularly for cells which strongly rely on mitochondrial function, such as neurons. 
In fact, m-AAA protease impaired activity causes different neurodegenerative diseases 
depending on the dysfunctional subunit. 
1.3.3.1  Paraplegin-associated neurodegenerative disease 
Hereditary spastic paraplegia (HSP) is an autosomal recessive neurodegenerative disease 
associated with axonal degeneration of the cortico-spinal neurons, which leads to weakness of 
the lower limbs and proprioceptive problems [147]. It is caused by mutations in several genes 
involved in mitochondria, ER, lipid droplets or cytoskeleton maintenance and function [148]. 
Mutations the SPG7 gene, localized in chromosome 16, which encodes for the m-AAA protease 
subunit paraplegin, are associated with HSP [149]. Several mutations of SPG7 have been 
reported [150]. This gene is highly expressed in big pyramidal neuron of the cortex [151] A 
Spg7 knockout mouse model was generated by eliminating, via homologous recombination, the 
first two exons of the gene [152]. Animals develop a progressive motor impairment starting 
between 4 and 5 months, axonal degeneration of motor neurons of the spinal tract, optic nerve 
and peripheral nerves, recapitulating the human disease phenotype. Moreover, mitochondrial 
abnormalities are also prominent in affected axons. An alternative splicing of the murine Spg7 
gene was described to incorporate into the ER, suggesting that the AAA protease could have a 
function in other cellular compartments [153]. In addition, a recent report suggested that 
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paraplegin is a conserved and core component of the MPTP, and that its disruption prevented 
Ca2+ imbalance and cell death [154]. 
1.3.3.2 AFG3L2 associated neurodegenerative diseases 
Mutations in AFG3L2 cause two different neurodegenerative diseases: spinocerebellar ataxia 
type 28 (SCA28) [155-157] and spastic ataxia neuropathy syndrome (SPAX5) [158, 159]. The 
disease are caused by missense, deletion, insertion or duplication mutations. 
SCA28 was firstly described in 2006 by Cagnoli et al., [160], as a novel form of autosomal 
dominant cerebellar ataxia (ADCA). It was observed in a 4-generation Italian family, where 
affected persons developed a slowly progressive cerebellar ataxia around 19-20 years of age. 
The condition always started with gaze-evoked nystagmus, difficulties in keeping balance while 
standing and gait incoordination. Cerebellar atrophy was also observed in affected individuals 
(Fig. 1.3). Through a genome-wide analysis, researchers were able to identify linkage with 
chromosome 18 markers. In 2010, Di Bella et al., [157] found out that different mutations in 
AFG3L2, specifically in exon 16, cause SCA28 in different unrelated Italian families. This was 
the first time that a mitochondrial protein was discovered to cause a form of spinocerebellar 
ataxia. In later years, more AFG3L2 mutations, in exons 10, 15 and 16, were linked to SCA28, 
further confirming the crucial role of this protease in the development of the disease [157, 161-
163].  
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Figure 1.3: Cerebellar atrophy in SCA28 affected patient. Sagittal and coronal MRI scans of patient 
affected by SCA28 [155].   
Autosomal recessive spastic ataxia neuropathy syndrome (SPAX5), caused by homozygous 
mutations in AFG3L2, is characterized by early-onset spasticity, ambulation impairment, 
dystonia, myoclonic epilepsy, oculomotor apraxia and cerebellar ataxia [158]. However, the 
symptoms have a variable severity, as observed by Muona et al., [159]. In vitro functional 
studies on yeasts showed that the mutation studied by Pierson and colleagues induces reduced, 
but not abolition, of the m-AAA protease homooligomers, and impaired assemble of both the 
homo and heterooligomers [158] 
In order to understand the pathology development and the functional impairment caused by 
AFG3L2 dysfunction, several murine models were generated [139, 151, 164-167]. Animals 
carrying a null mutation in the Afg3l2 gene, obtained by ectopic insertion in exon 14 of the 
murine leukemia virus insertion 66, in heterozygosis (Afg3l2+/Emv66) manifest a progressive 
motor impairment with imbalance, mitochondrial dysfunction and cerebellar Purkinje neurons 
degeneration starting at 4 months of age, whereas the spinal cord was unaffected [168]. The 
concomitant knockout of Spg7 in these animals (Spg7-/-:Afg3l2+/Emv66) induces a severe 
phenotype featuring ataxia, imbalance and tremor. Moreover affected animals develop an 
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axonopathy, faster than the Spg7-/- mice and cerebellar degeneration which occurs faster than 
in the Afg3l2+/Emv66 [151]. In the Afg3l2Emv66/Emv66 null mutant, where the AFG3L2 protein is 
completely absent, homozygosis leads to complete paralysis by postnatal day 16. The same 
phenotype was observed in animals carrying an amino acid mutation where an arginine residue 
was substituted by a glycine residue in position 389, in the AAA domain. In both models of 
SPAX5, carrying the homozygous depletion of AFG3L2, animals displayed spinal cord reduced 
axonal diameter and myelinated densities. Moreover, loss of large axons was observed, mostly 
due to developmental problems, as there is no sign of inflammation or reactive astrogliosis 
[164]. 
The Purkinje neurons (PCs) of the cerebellum appear to be sensitive to Afg3l2 mutations, also 
because of their high AFG3L2 protein levels [151, 157]. Almajan and colleagues [165] used a 
conditional knockout model, which targets PCs specifically using the L7 promoter to induce 
recombination via the Cre-LoxP system. Flanking exons 4 and 5 of the Afg3l2 gene with two 
LoxP site (Afg3l2fl/fl) allowed the selective deletion of the protein only in PCs. The cells 
developed respiratory deficiency and reduced mitochondrial ribosomal assembly, accompanied 
by mitochondrial morphological abnormalities and subsequent neuronal electrophysiological 
alterations and death. To complete the scene, reactive astrogliosis and neuroinflammation also 
occurred. Afg3l2 downregulation in primary neuronal cultures showed that mitochondrial 
anterograde transport is reduced due to tau hyper-phosphorylation [166]. However, the 
mechanism leading to cellular death is still elusive. Ca2+ concentration dysregulation seems to 
be implicated: according to Maltecca et al., [169, 170] Afg3l2 deficient mitochondria at the 
synaptic buttons are incapable of buffering Ca2+. The ion intracellular concentration increases 
in PCs following synaptic stimulation, and it activates calpains triggering a cell death 
mechanism called dark cell degeneration, as in semithin sections dying cells appear darker. 
Previously observed following glutamatergic excitotoxicity, dark cell degeneration causes 
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cytoplasmic condensation, vacuolated cytosol, chromatin aggregation but not apoptotic bodies 
and no signs of phagocytosis [171]. Dark cell degeneration was also observed in a conditional 
Afg3l2 knockout mouse model targeting myelinating cells in a Afg3l1 null background (Afg3l1-
/-) [167]. Afg3l1-/-: Afg3l2fl/fl mice were crossed with a Cre recombinase line driven by a 
proteolipid protein promoter (PLP-Crewt/tg), which gives specificity for myelinating cells. While 
Afg3l2fl/fl: PLP-Crewt/tg  and Afg3l1-/- mice do not show any phenotype up to 60 weeks, Afg3l1-
/-: Afg3l2fl/fl: PLP-Crewt/tg manifest an early-onset impaired motor coordination, reduced body-
weight and hair-greying. Mitochondria in targeted cells are highly fragmented and swollen with 
abnormal cristae morphology. Moreover, targeted cell loss and axonal abnormal myelination 
were observed. Despite the neurons have properly functional m-AAA proteases, animals 
manifest phenotype upon m-AAA protease dysfunction in myelinating cells, suggesting that 
glial cells dysfunction contributes to the neuronal demise [167].  
The assumption that Ca2+-mediated cell death could be the cause of PCs degeneration, seemed 
to find further proof in the work published by König and colleagues [138]. In fact, the authors 
showed that upon Afg3l2 deletion the EMRE-MCU gate-less complex is constitutively activated 
and mitochondria are flooded with excessive Ca2+, inducing the MPTP opening and massive 
release of the ion in the cytosol. This may lead to Ca2+-mediated cell death, being it apoptosis 
or dark cell degeneration. To further prove the Ca2+-mediated cell death, Maltecca et al., [170] 
used two different strategies, based on the rationale that increased Ca2+ concentrations in PCs 
are due to glutamatergic stimulation from the granule cells. In order to reduce it, they crossed 
the Afg3l2+/Emv66 mice with a line expressing a loss of function mutation of the metabotropic 
glutamate receptor 1 (mGluR1), in heterozygosis. The second strategy consisted in the 
administration to Afg3l2+/Emv66 mice of the antibiotic ceftriaxone, which increases the 
expression of EAAT2 receptors on astrocytes. In both cases, the authors were able to rescue the 
phenotype of Afg3l2+/Emv66 mice. Recently, a work from Patron et al., [139] aimed to ultimately 
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confirm or deny Ca2+ dysregulation as causative for PC death with a direct approach: 
Afg3l2fl/fl:L7-Crewt/tg mice were crossed with Mcufl/fl mice. Despite the reduced MCU levels and 
Ca2+ uptake by mitochondria, PCs fate was unchanged when compared to Afg3l2fl/fl:L7-Crewt/tg 
mice. This observation, according to the authors, rules out the possibility that Ca2+ imbalance 
per se is the cause of neuronal cell death in case of m-AAA protease impairment. 
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1.4 Mitochondrial function in astrocytes 
The distribution of the mitochondrial network in astrocytes was debated over the years. 
Protoplasmic astrocytes have many processes, and one single astrocyte can ensheat 100,000 
synapses in rodents [172]. However, their diameter varies between 20-200 nm in the peripheral 
astrocytic processes (PAPs). Considering mitochondrial diameter in other cell types could reach 
1 µm [173], it seemed unrealistic for PAPs to have mitochondria. However, it was extensively 
shown that astrocytes have an extended mitochondrial network in their PAPs [173-175]. 
Studies using FACS and acutely isolated astrocytes provided evidences of the predominant 
glycolytic profile of these cells [33, 45, 176]. The glycolytic profile of astrocytes is supported 
by studies showing that the pyruvate dehydrogenase kinase 4 (PDHK4) is highly expressed in 
astrocytes. PDHK4 phosphorylates the pyruvate dehydrogenase (PDH) and decreases its 
activity, favoring the conversion of pyruvate in lactate and decreasing OXPHOS activity [176, 
177]. Therefore, it is necessary to understand what, beside OXPHOS, mitochondrial are needed 
for in astrocytes. 
Despite the lack of excitability, meant as neuronal-like response, astrocytes react to neuronal 
activity with Ca2+ fluctuations. Despite the amplitude and the purpose of the varying calcium 
concentrations can differ, it was shown that small Ca2+ signaling microdomains occur in 
concomitant presence of mitochondria [178, 179]. The reason for mitochondrial localization at 
the place of the microdomains could be the requirement of ATP to fuel the pumps in charge of 
moving Ca2+ in various compartments inside and outside the cell. In fact, it was shown that 
increased Ca2+ concentration within the matrix is associated with increased ATP production 
rate in cardiac mitochondria [173]. Furthermore, nanomolar elevations of cytosolic calcium 
induce increased activation of the aspartate-glutamate carrier 1, which leads to increased 
NADH levels in mitochondria. This is suspected to increase mitochondrial respiration via 
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OXPHOS in a glutamate-dependent fashion [180]. In addition, it was shown that mitochondria 
are localized in proximity of astrocytes glutamate transporters EAATs [181]. EAAT2 transports 
inside astrocytes a molecule of glutamate together with Na+ and transports K+ outside the cell. 
The ions gradient is maintained by the Na+/K+ ATPase which, using the energy provided by 
ATP hydrolysis, pushes sodium outside the cell and potassium inside [182]. The Na+/K+ 
ATPase activity requires high amounts of ATP to fulfill its activity. It was proposed that the 
glutamate transported inside astrocytes by the EAATs is partially used to refuel the neuronal 
pools, but it is also partially converted to α-ketoglutarate and used for producing ATP via 
OXPHOS, to provide localized energy substrate for the Na+/K+ ATPase activity [183]. 
Mitochondria Ca2+ buffering can actually contribute to the astrocytic Ca2+ microdomains by 
releasing the ion via the Na+/Ca2+ exchanger NCLX or via the opening of the MPTP [173]. 
Mitochondrial relevance in regulation of Ca2+ transients was proposed. In fact, administration 
of the proton uncoupler carbonyl cyanide p-trifluoromethoxy-phenylhydrazone (FCCP), which 
causes the dissipation of mitochondrial membrane potential, induces not only the rate decay of 
the astrocytic Ca2+ transients, but also the increased spatial propagation of spontaneous 
transients as well as the increase of their amplitude [104, 178]. Furthermore, Ca2+ is required 
for mitochondria movement. These organelles accumulate in areas with elevated activity or 
high-energy demand, and it was previously reported that neuronal activity, glutamate uptake 
and inverse directionality of the NCLX block mitochondrial transport [181, 184]. In fact, 
mitochondrial movement requires the adaptor mitochondrial Rho-GTPase proteins 1 and 2 
(Miro1 and 2). The role of these proteins is to tether mitochondria to the motor proteins kinesin 
and dynein, which move the organelles along the microtubule network. The tethering occurs at 
low calcium concentration in astrocytes, and when intracellular Ca2+ increases following the N-
methyl-D-aspartate receptor (NMDAR) activation on astrocytes surface, miro proteins 
disassemble from the motor complex anchoring mitochondria to the activated area [178, 185]. 
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The fact that mitochondria are located at the spot of ~85% Ca2+ spontaneous microdomains, 
hinted to the hypothesis that they contribute to the intracellular ion-mediated signaling in the 
PAPs. To test this, Agarwal et al [186] blocked the MPTP using cyclosporine A and rotenone, 
and this reduced the spontaneous microdomains by 35%. Moreover, when adding picrotoxin to 
induce neuronal activation, they could detect reduced Ca2+ release from mitochondria, 
demonstrating that mitochondria in astrocytes are involved in the generation of calcium 
microdomains. 
1.4.1 Mitochondrial dysfunction in astrocytes and diseases 
In case of trauma or neurodegeneration, astrocytes are essential responders, and their 
mitochondrial network changes along with their activity: Motori and colleagues [174] revealed 
that, following stab wound injury on mice forebrain, mitochondrial network in astrocytes varies 
depending on their localization. In fact, astrocytes localized in the core lesion displayed a 
heavily fragmented mitochondrial network, whereas astrocytes in the penumbra area (i.e. the 
scar forming region) showed an elongated mitochondrial network, compared to the tubular 
network of the contralateral uninjured brain region. They also showed that the changes in the 
core lesion resolved within 10 days from the surgery, but in the penumbra area the 
mitochondrial network in astrocytes remained elongated up to 10 days. The altered 
mitochondrial dynamics are caused by pro-inflammatory stimuli, such as IL-1β, which also 
induce increased glycolytic rate and reactive oxygen species (ROS) production in fragmented 
mitochondria. Finally, the authors showed that mitophagic elimination of fragmented 
mitochondria restored the tubular network in the core-lesion area [174].  
Despite mitochondrial important role in astrocytic function and response to injury, very little is 
known about mitochondrial dysfunction in astrocytes and its relevance for neurodegeneration. 
Recently, two murine models of mitochondrial dysfunction in astrocytes have been published, 
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showing how astrocytic response to mitochondrial dysfunction is complicated [34, 187]. To 
evaluate the effect of impaired mitochondrial respiration in astrocytes, Supplie and colleagues 
generated a conditional mouse model in which the cytochrome c oxidase subunit COX10 was 
specifically depleted in adult astrocytes [34]. The assumption was that astrocytes, being 
considered glycolytic cells, survive OXPHOS deficiency. Indeed, this was the case, as mice did 
not display any phenotype. Further analysis did not show any cerebellar abnormality, nor cell 
death or neuroinflammation. Despite cerebellar astrocytes showed extensive OXPHOS 
deficiency, they survived by upregulation of aerobic glycolysis.  
Mitochondrial respiration seems to be dispensable for astrocytes survival. However, 
mitochondrial function in astrocytes is not limited to ATP production. Therefore, targeting 
different mitochondrial functions could reveal that these organelles are indeed essential for 
astrocytes survival. The Twinkle helicase is essential for mtDNA replication [188], and 
mutations in the gene encoding it causes the Alpers-Huttenlocher syndrome, characterized by 
cortical necrosis and spongiotic changes [189]. Ignatenko and colleagues worked on different 
murine models of Twinkle helicase knockout. While the full body knockout model was not 
compatible with life, conditional models targeting specifically neurons or astrocytes survived 
birth and developed till adulthood. However, both mouse models featured a neurodegenerative 
phenotype. Interestingly, the astrocyte-specific murine model showed the neurological 
impairment earlier than the neuronal-specific knockout, developing OXPHOS deficiency, 
secondary neuronal damage, inflammation and, importantly, spongiotic encephalopathy, which 
was not developed in the neuronal-specific line. The neuronal-specific knockouts showed signs 
of respiratory deficiency in neurons, apoptosis, reactive astrogliosis and inflammation. Despite 
the development, at 4-5 months, of the neurological phenotype was early-onset in the astrocyte-
specific model compared the neuronal-specific model, animals survived for an additional 4-5 
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months. The neuronal-specific mouse model on the other hand showed a late-onset phenotype, 
at 7-8 months, which quickly developed leading to death in less than two months [187]. 
To conclude, mitochondrial function in astrocytes is essential for OXPHOS, Ca2+ homeostasis, 
cell death inhibition as for other cells. Moreover, mitochondrial dysfunction in astrocytes is 
detrimental and potentially lethal, as it is for neurons, and goes beyond the respiratory 
efficiency.	
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2 AIM 
The aim of my thesis is understanding the contribution of astrocytes to the development of 
neuronal phenotypes associated with m-AAA protease dysfunction. I divided the aim in 3 
questions: 
• Is the m-AAA protease dysfunction lethal for astrocytes, as it is for neurons? 
• What is the effect of astrocytic m-AAA protease impairment in the cerebellum? 
• Does astrocytic m-AAA protease dysfunction affect PCs intrinsic properties and 
morphology? 
Of note, the murine models, as well as the cell culture experiments were mostly aimed to 
understand the pathophysiological causes of neuronal death upon m-AAA protease deficiency. 
The mechanism underlying neuronal death remains elusive. The m-AAA protease deficiency 
equals a death sentence for certain neuronal populations and it is crucial to understand how to 
revert neuronal damage. Moreover, different m-AAA protease subunits are linked to differential 
neuronal susceptibility, probably because different neuronal subpopulations have increased 
expression of one subunit respect to the other. In fact, it was shown that PCs express high levels 
of AFG3L2, while pyramidal neurons of the cortex express high levels of paraplegin [157, 190]. 
Furthermore, it cannot be excluded that different m-AAA subunit composition could cause 
selectivity for undetermined substrates, exponentially threatening specific neuronal 
subpopulations.  
However, it has to be considered that in human diseases caused by m-AAA protease 
dysfunction, neurons are not the only cells affected. The pathophysiological alterations in glial 
cells could also cause an additional stress on neurons, worsening the already serious condition 
of the cells. It was shown that alleviating the glutamatergic stimulation on PCs by increasing 
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the EAAT2 receptors on astrocytes ameliorates the phenotype in the SCA28 mouse model 
[170]. This finding suggests that astrocytes may have an unrecognized role in the development 
of the neurodegenerative disorders caused by m-AAA protease dysfunction in humans.  
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3 MATERIAL AND METHODS 
3.1 Mouse models 
Animal experiments took place in accordance with European (EU directive 86 /609/EEC), 
German (TierSchG), institutional guidelines and local authorities (Landesamt für Natur, 
Umwelt und Verbraucherschutz Nordrhein-Westfalen, Germany). Animals were kept in single 
ventilated cages, under 12h:12h day/night cycles. Food and water were provided ad libitum and 
animals were monitored for signs of motor impairment and distress. 
3.1.1 Astrocyte-specific Afg3l2 knock-out line (astro-L2 KO) 
Mice carrying two LoxP sites flanking exons 4 and 5 of Afg3l2 (Afg3l2fl/fl) gene were previously 
described [165, 167]. This conditional mouse line was crossed with the inducible GFAP-
CreERT line (hGFAP-Cretg/wt) [191]. The GFAP promoter gives specificity for targeting 
astrocytes, when induced after post-natal day 7 (P7) via tamoxifen injection. To minimize stress 
reaction on pups, intraperitoneal tamoxifen injections were administered to lactating mothers 
for five consecutive days. Control animals (Ctrl) used were hGFAP-Crewt/wt littermates. 
Furthermore, to visualize mitochondrial morphology and to identify targeted cells, we crossed 
the astro-L2 KO mouse line with the ROSA26+/SmY mice (mtYFPtg/+) [165, 167, 192]. 
3.1.2 Astrocyte specific m-AAA protease ablation mouse model (astro-
DKO) 
In order to obtain total ablation of the m-AAA protease, astro-L2 KO mice were crossed with 
full body Afg3l1 knock out mice (Afg3l1-/-). This mouse line was previously described [167] 
and does not show any phenotype up to 60 weeks. In this case control animals were Afg3l1-/- 
littermates (L1-/-)Furthermore, to visualize mitochondrial morphology and targeted cells, astro-
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DKO mice were crossed with the ROSA26+/SmY mice. The GFAP-Cre recombinase was induced 
as previously described. 
3.2 Tamoxifen injection procedure 
To induce the Cre-mediated recombination, intraperitoneal injection of tamoxifen (T5648, 
Sigma) was performed on lactating mothers. The drug was dissolved in a mixture of corn oil 
(Sigma) and pure ethanol 9:1, at the concentration of 20 mg/ml. Prior the injection, the mothers 
were weighted and the amount of tamoxifen used was calculated in order to administer 1 mg/10 
g of body-weight/day.  
3.3 Behavioral analysis 
3.3.1 Rotarod assay (performed by Steffen Hermans) 
To assess motor coordination, male and female astro-L2 KO mice and their respective controls 
were tested on a rotarod apparatus (TSE system) at 8, 32 and 62 weeks. Animals were trained 
for 1 minute on the steadily rotating rod at a speed of 4 rpm. During the actual test, animals 
were placed on the accelerating rod, starting with a speed of 4 rpm, with constant acceleration 
of 7.2 rpm up to a maximum of 300 seconds. The latency to fall was recorded. Three trials were 
performed on the same day, 15 minutes apart from each other.  
3.3.2 Ataxic score evaluation 
The ataxic score evaluation was performed as described previously [193]. It consists of four 
different tests and observations: ledge test, hind limbs clasping test, gait and kyphosis 
evaluation. Animals were scored 0 to 3, according to table 1, and the sum of the evaluations of 
each test determined the final score. Both male and female astro-DKOs and L1-/- mice were 
tested. 
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Table 1 - Ataxic phenotype score evaluation. 
 Score Ledge test Hind limb test Gait Kyphosis 
0 
no balance lost 
while walking-
lower itself back 
into the cage 
gracefully 
hind limbs 
outward 
move normally, 
bodyweight supported 
by all the limbs and both 
hind limbs participating 
straightened spine 
while walking, no 
persistent kyphosis 
1 
foot slips but overall 
coordinated 
one retracted limb 
more than 50% of 
suspended time 
tremors, limp while 
walking 
mild kyphosis but 
straightened spine 
2 
no hind limb grasp, 
land on its head 
both hind limbs 
partially retracted 
more than 50% of 
time 
sever tremor and limp, 
lowered pelvis, feet 
away from the body 
persistent but mild 
kyphosis 
3 
fall or nearly- 
refuses to move and 
shake 
entirely retracted 
for more than 50% 
of the time 
difficulty in moving, 
abdomen touching the 
ground 
persistent 
pronounced 
kyphosis walking or 
sitting 
3.4 Tissue collection 
3.4.1 Transcardial perfusion 
Animals were anesthetized with an intraperitoneal injection of a ketamine/xylazin mixture (100 
mg/10 mg per kg of bodyweight). Once unconscious, the abdominal cavity was opened to 
expose the heart. The needle was inserted in the left ventricle and the vena cava was severed 
close to the heart junction, so that the blood and the perfusion solutions could flow out of the 
body. Animals that were up to 4 weeks old were transcardially perfused with a 21 G scalp vein 
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set, while older animals were perfused with a 18 G scalp vein set (Ecoflo). Mice were first 
perfused with 1X phosphate buffer saline (PBS) for 5 minutes, then with 4% paraformaldehyde 
(PFA) in 1X PBS for an additional 5 minutes. Afterwards, organs were removed and placed in 
4% PFA or in 2% glutaraldehyde. 
3.4.2 Cervical dislocation 
When fresh tissue was required, mice were euthanized via cervical dislocation. The tissues were 
placed either in sucrose 15% for 4 hours, or post-fixed in 4% PFA for 24 hours or directly 
frozen in liquid nitrogen and stored at -80°C.  
3.5 Histological analyses 
3.5.1 Immunofluorescence stainings on free floating sections 
Tissues taken from transcardially perfused mice, were embedded in 6% agar and cut in 30 µm 
sagittal slices using a vibratome (VS1000, Leica). Sections were washed in tris-buffered saline 
(TBS) and post fixed with methanol. Permeabilization and blocking buffer was prepared with 
0.4% Triton X-100 (Fluka), and 10% goat serum in TBS and sections were incubated for 1 hour 
at room temperature (RT). Afterwards, sections were placed in the primary antibody solution 
(0.4% Triton X-100, and 5% goat serum in TBS) with single primary antibody or a combination 
of two antibodies (table 2) O/N at 4°C. Sections were then washed in TBS and incubated at RT 
for 2 hours with the secondary antibody solution (5% goat serum in TBS), with single antibody 
or a combination of two different ones (table 3). Following additional TBS washes and DAPI 
incubation (1:1000), sections were mounted on glass slides with Fluoro Save reagent 
(Calbiochem) and left for drying at 4°C O/N. Fluorescence images were acquired using Axio-
Imager M2 microscope equipped with Apotome 2 (Zeiss) and processed using the software 
AxioVision SE64 Rel. 4.9.1. For quantifications, 3 to 7 images from each staining were 
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manually counted using ImageJ software. At least 3 animals for each genotype at each time 
point were used for the experiments. The antibodies used are listed in table 2 and 3. 
Table 2 – Primary antibodies for immunofluorescence stainings 
Antibody Company Catalogue # Concentration 
Calbindin SWANT 300 1:500 
EAAT1  Miltenyi 5684 1:1000 
EAAT2 BD Transduction 611654 1:1000 
GFAP Cell Signaling 3670 1:500 
GFP Aves GFP-1020 1:500 
NG2 Millipore AB5320 1:250 
Iba1 Wako 019-19741 1:2000 
S100 DAKO Z0311 1:2000 
SMI31 Covenance SMI-31R 1:500 
SOX2 Abcam 979559 1:700 
vGlut2 SySy 135402 1:500 
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Table 3 – Secondary antibodies for immunofluorescence stainings 
α-chicken Alexa Fluor 488 Jackson Immuno research 703-545-155 1:500 
α-mouse Alexa Fluor 488 Molecular Probes A-11029 1:1000 
α-mouse Alexa Fluor 546 Molecular Probes A-21143 1:1000 
α-rabbit Alexa Fluor 488 Molecular Probes A-11034 1:1000 
α-rabbit Alexa Fluor 546 Molecular Probes A-11035 1:2000 
α-guinea pig Alexa Fluor 647 Molecular Probes A32728 1:1000 
α-rabbit Alexa Fluor 594 Molecular Probes A-21207 1:1000 
Streptavidin, Alexa Fluor 633 
conjugated  
Thermos Fisher S21375 1:400 
3.5.2 Electron microscopy (performed by Esther Barth) 
The cerebellum was dissected and post fixed in 2% glutaraldehyde (Sigma) in 0.12 M phosphate 
buffer at 4°C. The tissue was immerse in freshly prepared 2% glutaraldehyde the day before 
the embedding. The tissue was then immerse in 1% osmium tetroxide (Sigma) for up to 4 hours, 
dehydrated in ethanol gradient (50-100%) and propylene oxide. Once the embedding in Epon 
(Fluka) was solidified, the tissue was trimmed with an ultramicrotome (EM UC, Leica ) and 1 
µm sections were cut and stained with 1% toluidine blue for light microscopy. Furthermore, 70 
nm ultrathin sections were stained with 160 mM sodium hydroxide, 2% uranyl acetate (Plano 
GMBH), 3.52% sodium citrate (Electron microscopy sciences), 2.66% lead citrate (Electron 
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microscopy sciences). For imaging, the transmission electron microscope (JEOL 
JEM2100PLUS) equipped with GATAN OneView camera was used.  
Synapses were counted manually on acquired pictures (10000X) using ImageJ software. 
3.5.3 Immunohistochemistry on paraffin sections 
Following 4% PFA post-fixation, tissues were dehydrated in ethanol gradient (70-100%)  and 
xylene. The tissues were then embedded in paraffin, and cut in 5 µm sagittal slices using a 
microtome (RM2255, Leica). Selected sections were then deparaffinized with xylene and 
ethanol incubations, washed in PBS. Endogenous peroxidases were quenched by incubation in 
peroxidase quenching buffer (0.04 M NaCitrate, 0.121 M Na2HPO4, 0.013 M NaN3 and 3% 
H2O2). Following rinse in water, sections were boiled in 10mM NaCitrate buffer containing 
0.05% Tween-20 (pH 6) for 20 minutes, and cooled for additional 40 minutes to induce epitope 
retrieval. Permeabilization and blocking was performed with 1% albumin, 0.1% Triton X-100 
and 0.05% Tween-20. The cleaved caspase 3 Asp175 (Cell Signaling, 9661; 1:500) primary 
antibody incubation was performed O/N at 4°C in permeabilization and blocking buffer, 
together with Avidin D and Biotin from the Vectastain Blocking kit. Secondary biotinylated 
anti-Rabbit (Vector, BA-1000) antibody was then applied with Avidin D and Biotin from the 
ABC Kit Vectastain Elite. The staining was then visualized using the DAB chromogen and its 
substrate (Vector Laboratories). Three animals at each time-point were used for each genotype. 
The slides were then scanned with a slide scanner (SCN400, Leica) and analyzed with the 
software Aperio ImageScope (v12.3.2.8013). Positively stained cells were manually counted 
from 3 to 4 cerebellar sections/animal. 
3.5.4 COX-SDH histochemistry 
Animals were sacrificed via cervical dislocation, followed by cerebella dissection, the samples 
were immersed in 15% glucose for 4 hours and then in 30% sucrose O/N at 4°C. To facilitate 
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the cutting procedure, the tissue was embedded in OCT (Tissue Tek), frozen in dry ice and 
stored at -80°C till use. The cryostat (CM1850, Leica) was set at -21°C and tissues were 
equilibrated inside the machine for 20 minutes before cutting. 3 to 4 parallel sections of 10 µm 
were placed on each slide and kept at -80°C until the COX-SDH histochemistry was performed. 
On the experimental day, selected sections were air dried for 1 hour and then covered with COX 
solution: 5 mM 3,3 diaminobenzidine tetrahydrochloride (Sigma-Aldrich), 500 µM cytochrome 
c (Sigma-Aldrich) and Bovine catalase 2 mg/ml (Sigma-Aldrich). The slides were incubated 
for 40 minutes at 37°C in a humidified chamber. Following quick washes in PBS, the sections 
were covered with SDH solution composed of 1.875 mM nitroblue tetrazolium (Sigma-
Aldrich), 1.3 M sodium succinate (Sigma-Aldrich), 2 mM phenazine methosulphate (Sigma-
Aldrich) and 100 mM sodium azide (Sigma-Aldrich). The incubation took place at 37°C in a 
humidified chamber for up to 90 minutes. The slides were then scanned with a slide scanner 
(SCN400, Leica) and analyzed with the software Aperio ImageScope (v12.3.2.8013).  
3.6 Molecular Biology 
3.6.1 Genotyping and recombination assessment 
Genomic DNA was usually extracted from ear-punches and used for genotyping. However, to 
assess recombination in different tissues, genomic DNA was also extracted from livers, tails, 
forebrains and cerebella where indicated. The tissue was incubated O/N in lysis buffer (50 mM 
Tris-HCl pH 8, 100 mM NaCl, 100 mM EDTA pH 8, 0.5% SDS and 1 mg/ml proteinase K) at 
55°C. Following 10,000 g centrifugation at RT for 10 minutes, the supernatant was collected in 
a new tube. DNA precipitation was performed in 100% ethanol at 15,000 g centrifugation at 
4°C. The precipitated DNA was washed in 70% ethanol and centrifuged again at 15,000 g at 
4°C. The DNA was resuspended in 500 µl of TE buffer (10 mM Tris-HCl pH 8, 1 mM EDTA 
pH 8).For each sample, 7.5 µl of EmeraldAMP MAX PCR Master Mix (TaKaRa) were mixed 
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with 1 µl of each primer (10mM) and 0.5 µl of DNA. The final volume was adjusted to 15 µl 
by adding autoclaved water. The PCR program is reported in table 4, while the primers used 
are reported in table 5. 
Table 4 - PCR program for genotyping and recombination assessment 
Temperature Time Number of cycles 
95 °C 2 minutes 1 
95 °C 15 seconds 
34 58 °C 30 seconds 
72°C 45 seconds 
72°C 5 minutes 1 
 
Table 5 - PCR primers  
Locus Primer 
name 
Sequence (5´-3´) Amplicon size (bp) 
Afg3l2 
Wt/fl FW TTGGTTTTGTATGTGTTAGGTCAG Wt1: 387; 
Fl: 506 
Wt2: 1325 
Δ: 467 
Wt/fl RV GCCTGCACAGCTCCATGAT 
Δ RV ATTTGGAGCTGCGGGTTAG 
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Afg3l1 
Wt/KO 
FW 
GCATTGCACAGTCATTTCAGG 
Wt: 272 
KO: 509 Wt RV GCCGTGGGTAATGTTTGTTCC 
KO RV TGGACAGGGCATTATGATGC 
ROSA26 
Mt-YFP1 AAAGTCGCTCTGAGTTGTTAT 
Wt: 583 
Tg: 250 
Mt-YFP2 GCGAAGAGTTTGTCCTCAACC 
Mt-YFP3 GGAGCGGGAGAAATGGATATG 
CRE 
Cre1 (TL-
7677) 
GAACCTGATGGACATGTTCAGG Tg: 320 
Cre2 (TL-
7678) 
AGTGCGTTCGAACGCTAGAGCCT 
House-
keeping1  
(TL-7901) 
GGAGCGGGAGAAATGGATATG 
Wt: 250 
House-
keeping2  
(TL-7902) 
TGGGCTGGGTGTTAGTCTTA 
Wt= wild type, FW= forward; RV= reverse. 
Material and Methods 
 
47 
 
3.6.2 RNA extraction and quantitative real time PCR 
Animals were quickly sacrificed via cervical dislocation. Brain and forebrain were dissected, 
snap frozen in liquid nitrogen and stored at -80°C. The tissue was homogenized in Trizol 
(Thermo Fisher Scientific) using a precooled hand-homogenizer. After adding chloroform, 
samples were centrifuged at 12,000 g at 4°C for 15 minutes and the aqueous phase of the 
mixture was transferred to a new tube. The RNA was then precipitated for 10 minutes at 12,000 
g centrifugation at 4 °C in isopropanol. The RNA pellet was then washed in 75% ethanol and 
dried at room temperature. The pellet was resuspended in 50 µl of ultrapure water and store at 
-80°C till use. SuperScript™ First Strand Synthesis System (Thermo Fisher Scientific) was use 
to retro-transcribe 2 µg of total RNA. Random hexamer primers were used according to the 
manufacturer instructions. The resulting cDNA was diluted 1:10 in double distilled water and 
the real time PCR was performed using the SYBR® green master mix (Thermo Fisher 
scientific) and 600 nM of each primer (table 7). Duplicates or triplicates of each sample were 
analyzed for each gene. The Quant Studio 12K Fex Real-Time PCR System thermocycler 
(Thermo Fisher Scientific) was used with the program indicated in table 6. The fold increase 
was determined with the formula 2(−ΔΔCt) and HPRT1 was used for normalization. 
Table 6 – PCR program for quantitative real time PCR 
Temperature Time Number of cycles 
95°C 10 minutes 1 
95°C 15 seconds 40 
65°C 1 minute 
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95°C 15 seconds 1 
60°C 1 minute 1 
95°C 15 seconds 1 
 
Table 7 – Quantitative real time PCR primers 
Primer name Sequence 5´-3 
HPRT1 forward TCCTCCTCAGACCGCTTTT 
HPRT1 reverse CATAACCTGGTTCATCGC 
TNFα forward CTTCTGTCTACTGAACTTCGGG 
TNFα reverse CAGGCTTGTCACTCGAATTTTG 
IL-1β forward GAAATGCCACCTTTTGACAGTG 
IL-1β reverse TGGATGCTCTCATCAGGACAG 
IL-6 forward TAGTCCTTCCTACCCCAATTTCC 
IL-6 reverse TTGGTCCTTAGCCACTCCTTC 
PSAT1 forward AGTGGAGCGCCAGAATAGAA 
PSAT1 reverse CTTCGGTTGTGACAGCGTTA 
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PHGDH forward GACCCCATCATCTCTCCTGA 
PHGDH reverse GCACACCTTTCTTGCACTGA 
MTHFD2 forward CTGAAGTGGGAATCAACAGTGAG 
MTHFD2 reverse GTCAGGAGAAACGGCATTGC 
Fadd forward CGCCGACACGATCTACTG 
Fadd reverse GGCCAGTCTTTTCCAGTCTC 
RIPK1 forward GGAAGGATAATCGTGGAGGC 
RIPK1 reverse AAGGAAGCCACACCAAGATC 
RIPK3 forward ACCCCACCGAATCCAATG 
RIPK3 reverse AGTTCCCAATCTGCACTTCAG 
MLKL forward ACTGTGAACTTGGAACCCTG 
MLKL reverse TGCTGATGTTTCTGTGGAGTG 
ZBP1 forward TGTTGACTTGAGCACAGGAG 
ZBP1 reverse TTCAGGCGGTAAAGGACTTG 
BAK forward TGATATTAACCGGCGCTACG 
BAK reverse AGCTGATGCCACTCTTAAATAGG 
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PUMA forward AGGAAGATCGGAGACAAAGTG 
PUMA reverse AGCACACTCGTCCTTCAAG 
MCL1 forward TTGTAAGGACGAAACGGGAC 
MCL1 reverse TCTAGGTCCTGTACGTGGAAG 
3.7 Biochemistry 
3.7.1 Amino acid extraction (performed by Dr Susanne Brodesser) 
Snap frozen cerebella from cervically dislocated animals were thawed and weighted. 
Homogenization of the samples was performed with the Precellys 24 Homogenisator (Peqlab) 
at 6,500 rpm for 30 seconds in ice-cold acetonitrile/0.3 % formic acid 1:1 (v/v) (10 µl/mg 
tissue). Protein concentration was determined using bicinchoninic acid. A 1:10 diluition of 
internal standard mixture of isotope-labeled amino acids (Sigma) was added to the samples. 
Proteins were then precipitated with methanol via a 12000 g centrifugation for 5 minutes at 4°C 
and the supernatant was dried in autoinjiector vials with nitrogen steam. The dried amino acids 
extracts were derivatized with 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate and the 
AccQ-Tag Ultra Derivatization Kit (Waters). 
3.7.2 Liquid Chromatography -Electrospray Ionization Tandem Mass 
Spectrometry (performed by Dr Susanne Brodesser) 
In order to evaluate amino acid levels, samples were treated for Liquid Chromatography 
coupled to Electrospray Ionization Tandem Mass Spectrometry (LC-ESI-MS/MS) with a Core-
Shell Kinetex C18 column (150 mm × 2.1 mm ID, 2.6 µm particle size, 100 Å pore size, 
Phenomenex) and the QTRAP 6500 triple quadrupole/linear ion trap mass spectrometer 
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(SCIEX) was used for detection. The liquid chromatography (1260 Infinity Binary LC System, 
Agilent) was performed at 40°C  with a rate flow of 0.4 ml/minute, a mobile water phase with 
0.1% formic acid and acetonitrile containing 0.1% of formic acid (AFsolution). The latter was 
used for column equilibration for 1 minute. Sample injection was accompanied with linear 
changes in AF solution from 3% to 95% and back to 3% for a total time of 18.4 minutes. For 
derivatized amino acids evaluation, the positive ion mode was used, together with their specific 
Multiple Reaction Monitoring (MRM) transitions (Waters). For integration of the 
chromatogram peaks of internal standards and endogenous amino acid derivates, the software 
Analyst ver. 1.6.3 (SCIEX) was used. Serially diluted synthetic amino acid standard solutions 
within the range of 0.0 to 27.5 pmol on column were used to quantify endogenous amino acids. 
Each dilution was charged with known amount of isotope-labeled internal standards. Linearity 
and correlation coefficients (R2) of the calibration curves were obtained via linear regression 
analysis. R2 of the calibration curves were >0.99. normalization of endogenous amino acids 
was calculated to the wet weight of the tissue. 
3.7.3 Protein extraction for western blot 
Animals underwent quick cervical dislocation and the forebrain and cerebellum were snap 
frozen in liquid nitrogen and stored at -80°C till use. Lysis occurred in RIPA buffer containing 
50 mM Tris-HCl pH7.4, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1% sodium 
deoxycholate, 0.1% SDS, and protease cocktail inhibitor (P2714, Sigma) on ice using a Potter 
S homogenizer (Sartorius) at 1000 rpm. Following the homogenization, the lysates were kept 
at 4°C for 30 minutes and additionally centrifuged at 20000 g for 30 minutes at 4°C. The 
supernatant was transferred to a new tube and the protein concentration analyzed using the 
Bradford assay (Bio-Rad Laboratories). The proteins were diluted to the desired concentration 
in SDS-sample buffer containing 50 mM Tris-HCl pH 6.8, 2 % SDS, 10 % glycerol, 0.004 % 
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bromophenol blue and 1 % of β-mercaptoethanol. Samples were then boiled for 5 minutes at 
95°C and stored at -20°C.  
3.7.4 Western Blot 
50 µg of proteins were resolved in 10% poly-acrylamide gels containing 0.1% SDS in running 
buffer (25 mM Tris, 192 mM glycine, 0.1% SDS) at  constant 30 mA per gel. A protein marker 
was also used to identify the size of protein bands (PageRuler™ Plus Prestained Protein ladder, 
Thermo Fisher Scientific). Afterwards, proteins were transferred onto 0.45 µm PVDF 
membrane (GE Healthcare) in blotting buffer (25 mM Tris, 192 mM glycine and 20% 
methanol) at constant 300 mA for 90 minutes at 4°C. To assess that the transfer occurred and 
evaluate the homogeneous protein concentration of the samples, the membranes were stained 
with the Ponceau solution containing 0.1% Ponceau S in 5% acetic acid. Following short 
reactivation in methanol and a quick wash in TBST (0.1% Tween 20 in TBS), the membranes 
were first incubated in 5% milk (in TBST) at RT for 1 hour, and then in primary antibody at 
4°C O/N. After 3 10-minute washes in TBST, the membranes were incubated for 1 hour at RT 
with secondary antibodies diluted in 5% milk. After 3 more 10-minute washes in TBST, the 
membranes were incubated with enhanced chemiluminescent (ECL) detection reagents (GE 
Healthcare) and developed using X-ray films (FUJIFILM). Antibodies used are listed in table 
8. 
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Table 8 – Antibodies for Western blot 
 Antibody Company # Catalogue Dilution 
Primary 
antibodies 
Gephyrin/3B11 Schwarz lab  Home-made 1:50 
α-RIPK3 Cell Signalling,  15828S 1:1000 
α-Pan-actin Millipore  MAB1501R 1:4000 
Secondary 
antibodies 
HRP-linked α-mouse lgG Sigma-Aldrich  A9044 1:20000 
HRP-linked α-rabbit lgG  Sigma-Aldrich  A0545 1:10000 
3.8 Electrophysiological recordings (performed by Dr Simon 
Hess) 
4 weeks old L1-/- and astro-DKO mice (25-33 days of age) were anesthetized with isoflurane 
(AbbVie Deutschland GmbH and Co KG) and decapitated. Cerebella were quickly dissected 
and 300 µm sagittal slices were cut with a microtome (HM-650, Thermo Fisher) in a 4°C, 
carbogenated (95% O2 and 5% CO2) glycerol-based modified artificial cerebrospinal fluid 
(GaCSF) containing 250 mM Glycerol, 2.5 mM KCl, 2 mM MgCl2, 1.2 mM NaH2PO4, 10 mM 
HEPES, 21 mM NaHCO3, 5 mM glucose (pH 7.2), with ~310 mOsm. Sections were then 
transferred to a carbogenated artificial cerebrospinal fluid (aCSF) and kept for 20 minutes at 
35°C. aCSF composition was the following: 125 mM NaCl, 2.5 mM KCl, 2 mM MgCl2, 2 mM 
CaCl2, 1.2 mM NaH2PO4, 21 mM NaHCO3, 10 mM HEPES, and 5 mM glucose (pH 7.2) 
resulting in an osmolarity of ~310 mOsm. Sections were acclimatized at RT for minimum 30 
minutes before recording. Experimental chambers were filled with 3 ml continuously 
superfused with aCSF (2 ml·min-1). Experiments were carried out at 32°C. A fixed-stage upright 
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microscope was used to visualize neurons in the slices (BX51WI; Olympus). PCs were 
identified by their location within the cerebellar cortex. Current clump recordings were obtained 
with a a modified ELC03-XS amplifier (NPI Electronic) controlled by the PatchMaster software 
(version 2.32; HEKA). Data were sampled every 20 µs (50 kHZ) with a CED 1401 using Spike2 
(both Cambridge Electronics).  Perforated patch clamp was performed as previously described 
[165, 194, 195]. Briefly, ATP and GTP free patching pipettes were filled with a solution 
containing 128 mM Kgluconate, 10 mM KCl, 10 mM HEPES, 0.1 mM EGTA, 2 mM MgCl2 
(pH 7.3) with an osmolarity of ~300 mOsm.  Furthermore, 0.02% tetraethylrhodamine-dextran 
(D3308, Invitrogen) and amphotericin-containing internal solution (~200-250 µg·ml-1; G4888; 
Sigma). Amphotericin was dissolved in dimethyl sulfoxide (final concentration: 0.1 - 0.3%; 
DMSO; D8418, Sigma) and was added to the modified pipette solution shortly before use. The 
aCSF containing 10-4 M picrotoxin (P1675; Sigma-Aldrich), 5 x 10-5 M D-AP5 (A5282; Sigma-
Aldrich), and 10-5 M CNQX (C127; Sigma-Aldrich) allowed to shut off synaptic glutamatercic 
and GABAergic stimuli. Membrane resistance was evaluated via injection of hyperpolarizing 
current pulses. Evoked action potential firing was evaluated via injection of depolarizing 
currents (100 pA to 1000 pA in 100pA increments; 1.5s duration), determining the number of 
action potentials. Recorded cells were labeled with 1% biocytin (B4261, Sigma), fixed with 
Roti-Histofix (P0873, Carl Roth) and incubated with Alexa Fluor 633- conjugated streptavidin 
for 2 hours and fluorescent images were acquired with a confocal microscope (SP-8, Leica). 
3.9 Statistical analysis 
Two-tailed unpaired Student´s t test was applied to data sets using the software GraphPrism, 
v.6.07. Graphs represent mean± standard deviation (SD) or mean± standard error of the mean 
(SEM). When statistically significant, the p value is indicated in the graphs.  
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For electrophysiological studies, data analysis was performed with Spike2 (Cambridge 
Electronics) Igor Pro and GraphPad Prism v5.0b.  
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4 RESULTS 
4.1 Specific targeting of Bergmann glia in the mouse cerebellum 
with an inducible GFAP-driven Cre-LoxP system 
To analyze the astrocyte-specific effect of m-AAA protease dysfunction, I took under 
consideration two different aspects: which animal model to use, and how to induce the desired 
mutations in the cell type of interest. As animal model, I decided to use mice because of the 
structural similarities between mouse and human brains. Moreover, murine models 
recapitulating the m-AAA protease-related human diseases SCA28, SPAX5 and HSP were 
previously published [152, 168].  
Considering my aim to target astrocytes and no other cell types, I decided to use a conditional 
knockout system. Cre recombinase is largely used to specifically induce deletion of portions of 
genes [196]. This enzyme, derived from bacteriophage P1, is able to induce site-specific 
recombination between two DNA recognition sites (LoxP) [197]. Nowadays, the Cre-LoxP 
system is widely used to target specific cell types within organisms. To achieve the specificity 
required, it is necessary to use a cell type specific-promoter upstream to the Cre sequence. In 
order to target astrocytes, I decided to use the human GFAP promoter (hGFAP). The advantage 
of this promoter is that it is expressed mainly in astrocytes after postnatal day 7. The 
disadvantage is that before that, it is expressed also in neuronal precursors [198]. To overcome 
the expression of the recombinase in precursors, I used an inducible form of Cre recombinase, 
downstream to the hGFAP promoter (hGFAP-Cretg/wt) [191]. In the hGFAP-Cretg/wt mouse line, 
animals carry a Cre recombinase fused to modified estrogen receptors (CreER): their task is to 
translocate the recombinase to the nucleus, where it can act on the DNA. The receptors need to 
bind a specific drug, called tamoxifen, to move to the nucleus. The advantage of this system is 
that I have control over the Cre recombinase activity and the resulting recombination. 
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Moreover, in order to visualize which cells are indeed targeted following the recombination, I 
crossed hGFAP-Cretg/wt mice with the mitochondrial conditional reporter line expressing the 
yellow fluorescent protein (YFP) fused with a mitochondria targeting sequence (MTS) in the 
ROSA26 (ROSA26+/SmY) locus. The stop codon on the ROSA26 locus is flanked by two LoxP 
sites, and, following Cre recombinase activation, the stop codon is removed and the 
mitochondrial YFP (mtYFP) is translated [192]. To induce the Cre recombinase, tamoxifen 
administration was performed on lactating mothers, starting when pups were 7 days old, 
once/day for 5 consecutive days (Fig. 4.1A).  
Chow and colleagues demonstrated that astrocytes of the cerebellum (CB) are highly targeted 
with the hGFAP-Cretg/wt [191]. The cerebellar cortex is composed of three different layers. The 
most internal is the granule cells layer (GCL), where the glutamatergic granule neurons (GCs) 
reside. The Purkinje cell layer (PCL) contains the GABAergic PCs, which are located one close 
to the other in a monolayer. Finally, the molecular layer (ML) is the area where the synaptic 
contact between GC axons (parallel fibers) and the PC dendrites occurs. The PCL contains also 
the cell bodies of specialized radial astrocytes, called Bergmann glia (BG). These cells send 
their projections in the ML, and modulate the synaptic signals on the PC dendrites [199] (Fig. 
4.1B).  
The expression of the mtYFP highlights targeted cells, facilitating their identification. I used 
specific markers for PCs, parallel fibers and BG to perform immunofluorescence staining on 
cerebellar slices. PCs where stained with calbindin, a Ca2+-binding protein highly expressed in 
their cell body and dendrites [200]. Parallel fibers were stained with an antibody against 
phosphorylated neurofilament H and M, SMI31 [201]. BG was stained using the S100 marker, 
a Ca2+-binding protein expressed in glial cells that marks both cell body and projections of BG 
[202, 203]. The mtYFP signal perfectly co-localized with the S100 staining of BG, whereas no 
co-localization was detected between mtYFP and calbindin, nor SMI31 (Fig. 4.1C-E). 
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Therefore, I could conclude that BG are highly targeted with the designated hGFAP-Crewt/tg, 
and that the mtYFP is a reliable tool to visualize both targeted cell and mitochondrial 
morphology. 
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Figure 4.1: hGFAP promoter successfully targets astrocytes and not neurons when tamoxifen is 
administered starting at P7. (A) Strategy used to obtain transgenic mouse line expressing mtYFP in 
astrocytes. Lactating mothers (hGFAP-Crewt/wt) were injected with tamoxifen as indicated in the scheme 
(B) Schematic representation of the three layers of the cerebellar cortex and the 3 cell types under 
analysis. BG uptake glutamate (Glut) from the synaptic cleft, convert it to glutamine (Gln) and transport 
it to GCs, which use it produce Glut and restore their vesicles. (C-E) Immunofluorescence staining of 
cerebellar sections. mtYFP endogenous signal is represented in green, markers for astrocytes (S100), 
PCs (calbindin) and parallel fibers (SMI31) are indicated in red. Co-localization was detected only 
between mtYFP and S100 staining. n=3, scale bars= 20 µm.  
4.2 Generation of two mouse models of m-AAA dysfunction in 
astrocytes 
The fact that the GFAP-Cre is active in the BG is of relevance as mutations in AFG3L2 in 
humans cause cerebellar atrophy [155, 157]. In a previous study, Almajan and colleagues 
reported the use of a conditional mouse line, in which exons 4 and 5 of the Afg3l2 gene were 
flanked by two LoxP sites (Afg3l2fl/fl), and a Cre recombinase under the L7 promoter allowed 
to specifically induce the recombination on PCs. Upon Cre activation, the cut in the alleles leads 
to the insertion of a premature stop codon and deletion of the functional protein [165]. To 
investigate the effect of the m-AAA protease dysfunction in astrocytes, and its outcome in the 
cerebellum, I crossed Afg3l2fl/fl mice [165] with the inducible GFAP-Cre mouse line [191], 
resulting in the following genotype: Afg3l2fl/fl: hGFAP-Cretg/wt, from now on called astro-L2 
KO mice. The activation of the Cre recombinase was induced by intraperitoneal tamoxifen 
administration to the lactating mothers, starting when pups were 7 days old (Fig. 4.2A). To 
ensure that the recombination occurs, I extracted DNA from the forebrain, cerebellum, tail and 
liver from astro-L2 KO mice. I used the primers indicated in table 5 as Afg3l2 wt/fl forward, 
the Afg3l2 Δ reverse and the PCR program indicated in table 4. The strategy used is that the 
Afg3l2 Δ primer binds to a region downstream to the cutting site. If the recombination occurs, 
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the PCR product would be a 467 bp band. In case the recombination is unsuccessful, the PCR 
product is a hardly detectable 1325 bp band. The hGFAP-Cretg/wt recombines in the forebrain 
and cerebellum, but not in liver and tail, indicating that the Cre is not active in other organs 
(Fig. 4.2B).  
Astro-L2 KO mice have some residual m-AAA protease, as mice express a third m-AAA 
protease subunit called Afg3l1. AFG3L1 protein creates homooligomeric complexes and 
heterooligomeric complexes, together with paraplegin, and can compensate the AFG3L2 
deletion [122, 167]. To obtain the complete elimination of the m-AAA protease in astrocytes, I 
crossed the astro-L2 KO mice together with the Afg3l1 full body knockout (Afg3l1-/-) mouse 
line [167], resulting in the following genotype: Afg3l1-/-:Afg3l2fl/fl: hGFAP-Cretg/wt (defined as 
astro-DKO) (Fig. 4.2C). Animals ablated of the AFG3L1 subunit of the m–AAA protease (L1-
/-) do not show any phenotype up to 60 weeks of age [167], and where used as controls for the 
astro-DKO mouse line. Animals were then analyzed at different time points, as indicated in 
figure 4.2 (Fig. 4.2A and C).  
Results 
 
62 
 
 
Figure 4.2: Schematic representation of the mouse models studied, the strategy adopted for the 
Cre induction and the analysis time points. (A) Transgenic mouse lines used to generate the astro-L2 
KO mice. Lactating mothers (Afg3l2fl/fl) were injected with tamoxifen as indicated in the scheme. The 
litters were analyzed at 8, 32 or 62 weeks. (B) Recombination assessment from DNA extracted from 
tail, liver, forebrain and cerebellum of an astro-L2 KO male mouse at 8 weeks. The PCR band at 467 bp 
shows that recombination occurs only in the forebrain and cerebellum. (C) Transgenic mouse lines used 
to generate the astro-DKO mice. Lactating mothers (Afg3l1-/- : Afg3l2fl/fl) were injected with tamoxifen 
as indicated in the scheme. The litters were analyzed at 3 and 4 weeks. 
4.3 Phenotypical evaluation of astro-L2 KO and astro-DKO mice 
To characterize the mouse models, I started to closely monitor the weight of both male and 
female astro-L2 KOs and their control littermates (Ctrl, genotype: Afg3l2fl/fl). Both male and 
female astro-L2 KOs have decreased body-weight compared to Ctrl (Fig. 4.3A and B). Despite 
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this, the animals survive up to 62 weeks of age (latter time point used for the analysis) and do 
not show a prominent motor impairment by visual inspection. To further investigate any sign 
of motor impairment hard to detect in animals freely moving in their home cage, I decided to 
test them with the rotarod assay at different time points (indicated in Fig. 4.2A). The rotarod 
assay is used to assess motor coordination and can also be used to test memory skills in rodents. 
It consists of an apparatus provided with a rotating rod on which mice are positioned. While the 
rod accelerates, the mice have to walk to stay on it, for a maximum of 300 seconds. Sensors on 
the grid beneath the rod allow to automatically register the latency to fall of the animals. Motor 
coordination is necessary to maintain the position on the rotating rod [204]. Following a short 
training, animals were tested 3 times, 15 minutes apart by Steffen Hermans. Astro-L2 KO male 
mice show a decreased latency to fall, starting at 32 weeks, while female astro-L2 KO animals 
do not show any motor impairment at any time point analyzed (Fig 4.3 D-H).  
The astro-DKO pups were indistinguishable from their L1-/- littermates up to 3 weeks. However, 
by the forth week of age astro-DKO animals showed a significant lower body-weight (Fig. 4.3I-
J), independent from the sex of the animals. In order to assess ataxia, I performed 4 tests as 
described by Guyenet and colleagues [193]. The ledge test consists in positioning an animal on 
the edge of its home cage, and monitoring both how the animal walks and how it descends 
inside the cage. astro-DKOs were not able to walk on the edge of the home cage, as they had 
difficulties grasping the surface with their hind limbs, and were so uncoordinated that they were 
letting themselves fall into the cage. The second test consists in evaluating the curvature of the 
spine, looking for signs of pronounced kyphosis, which indeed was pronounced in astro-DKOs. 
The gait evaluation aims to assess if the animals are able to walk, the orientation of the hind 
limbs and the general ability to move: astro-DKOs walked with the hind limbs at about 45° 
angle respect to the body, and also were unable to stand on their hind limbs for a prolonged 
time. Finally, the hind limb clasping consists in holding a mouse by the tail and checking if the 
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hind limbs are oriented away from the body, or if they are retracted towards the body. The latter 
was indeed observed in astro-DKOs. Each test received an evaluation score between 0 to 3, 
with 3 being severely affected. The final score for each animal consists in the sum score of the 
4 tests (Fig. 4.3K). astro-DKO mice show a statistically significant increase in the ataxic score, 
compared to the L1-/-  (Fig. 4.3K). 
To conclude, both mouse models showed decreased body-weight compared to the respective 
controls, and these data suggest that m-AAA protease dysfunction in astrocytes is enough to 
induce a motor impairment in affected animals. 
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Figure 4.3: m-AAA protease impairment and ablation in astrocytes lead to neurological 
phenotypes. (A-B) Body-weight evaluation of male and female mice. n is indicated in the columns. (C-
H) Males and females latency to fall off the rotarod at different time points. n is indicated in the legend 
for each group at each time point. (I) Picture showing a L1-/- and an astro-DKO mice at 4 weeks. (J) 
Body-weight evaluation of L1-/- and astro-DKOs at 3 and 4 weeks. n is indicated in the columns. (K) 
Ataxic score evaluation. Each dot represent one animal. Data represent mean±SEM, the p value was 
calculated with the Student´s t-test, and is indicated on the respective graphs when ≤ 0.05. 
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4.4 m-AAA protease depletion induces mitochondrial 
fragmentation, aberrant cristae morphology and loss of 
targeted cells 
An extensive amount of evidences shows that m-AAA protease impairment, or loss, leads to 
mitochondrial fragmentation and aberrant cristae morphology [117, 164, 165, 167-170]. It has 
been proposed that the reason behind this is that the m-AAA protease dysfunction induces 
hyper-activation of OMA1, which, by cleavage of mitochondrial pro-fusion protein OPA1, 
shifts the mitochondrial fusion/fission balance towards fission [116-118]. In order to evaluate 
mitochondrial morphology in astro-L2 KO and astro-DKO mice, I crossed both lines together 
with the mtYFP reporter line. The expression of mtYFP is controlled by the Cre recombinase 
as previously described (Fig. 4.1A) [191], allowing me to directly monitor mitochondrial 
morphology and distribution in the ML. The mtYFP signal clearly shows mitochondrial 
fragmentation in both models, compared to the respective control animals (Fig. 4.4 A and B). 
Interestingly, the organelles appear fragmented prior to the development of the motor 
phenotype (Fig. 4.3 C-E and J-K). Moreover, mitochondrial distribution appeared altered in 
both models: the mtYFP signal in Ctrl animals of both models (in Fig. 4.4A, genotype Afg3l2wt/fl 
: hGFAP-Cretg/wt) appears stretched all over the extension of the ML, whereas in astro-L2 KOs 
and astro-DKOs the mtYFP signal does not reach the upper part of the ML in the latter time-
points analyzed. This suggests that mitochondria are retracted from BG projections or that the 
entire projection is retracted and does not reach the upper part of the ML.  
Another advantage of using a reporter line is that the fate of targeted cells can be monitored. 
By manual counting of mtYFP-positive (mtYFP+) cell bodies, I could show that targeted cells 
in the astro-L2 KO and astro-DKO models are decreased at 32 weeks and 4 weeks, respectively 
(Fig. 4.4 C and D), hinting to the possibility that targeted cells die. In the astro-L2 KO line, the 
number of targeted cells is comparable to Ctrl animals at 8 weeks. However, mitochondrial 
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fragmentation is already visible at 3 weeks (Fig. 4.4A). This means that mitochondria in 
targeted cells are fragmented for several weeks before animals manifest the motor impairment. 
In contrast, the motor impairment in astro-L2 KOs correlates with the demise of targeted cells.  
To better characterize mitochondrial morphological changes, I performed ultrastructural 
analysis of BG mitochondria, together with Esther Barth. Visual identification of the PCL was 
possible due to the higher electron-density of their cytoplasm compared to other cells, and due 
to their size, as they are bigger than other cells in the CB [199]. BG cells were also easy to 
identify because of their localization close to the PCs, and their nuclear structure [199]. BG of 
both KO lines showed aberrant mitochondria in their cytosol. In line with previous reports on 
neurons and oligodendrocytes depleted of Afg3l2, mitochondria are not only fragmented, but 
also depleted of cristae, swollen and less electron-dense compared to the respective controls 
(Fig. 4.4 E and F) [165, 167]. Interestingly, I was not able to find any aberrant mitochondria in 
BG of astro-L2 KO mice at 62 weeks, further hinting to the targeted cell death over time. 
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Figure 4.4: m-AAA protease depletion causes mitochondrial abnormalities and loss of targeted 
cells. (A-B) mtYFP endogenous signal shows early mitochondrial fragmentation in astro-L2 KO and 
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heterozygous mice (astro-L2 HET), and astro-DKO mice. n=3 for each group at each time point. Scale 
bar= 20 µm; scale bar enlargements= 10 µm. (C-D) Quantification of mtYFP+ cell bodies in the PCL. 
Dots represent n, data is indicated as mean±SEM, p value was obtained by Student´s t-test and indicated 
in the graphs when ≤0.05. (E-F) Ultrastructural analysis of BG mitochondria in astro-L2 KOs and astro-
DKOs compared to the respective controls. n≥3 for each group at each time point. Scale bar=500 nm. 
4.5 m-AAA protease function is necessary for BG survival 
The decreased number of targeted cells quantified via the mtYFP signal, together with the 
limited expansion of the fluorescent signal through the ML, suggested that BG morphology 
might be affected. In order to evaluate it, I stained CB sections with an antibody against the 
calcium-binding protein S100. BG structure appeared different in males and females astro-L2 
KO at 62 weeks, as if the females have a delayed phenotype (Fig. 4.5A and S1). This correlates 
with the absence of motor impairment observed in females. Therefore, I mainly focused on 
males for the analysis, but performed most of the CB stainings on females as well at 62 weeks 
(Fig. S1 and 2). BG projections in astro-L2 KO males appeared comparable to Ctrls at 8 weeks: 
the cell bodies located in the PCL and the projections elongated across the longitudinal plane 
of the ML, in line with what I detected with the mtYFP signal. However, at 32 weeks some BG 
cell bodies seemed to migrate into the ML, and the projections appeared shorter and not 
reaching the edge of the ML. The translocation of BG has been reported also in the vanishing 
white matter disease (VWM) [205]. The shorter projections in astro-L2 KOs observed with the 
S100 marker recapitulated the results from the mtYFP endogenous signal, which showed a 
retracted pattern (Fig. 4.4A). At 62 weeks of age, the situation seemed to worsen, as there were 
more BG cell bodies in the ML in the astro-L2 KO cerebella. I counted the S100-positive 
(S100+) cell bodies in the PCL to validate the results obtained from the mtYFP+ cells 
quantification. The number of S100+ cells was, indeed, reduced at 32 weeks, but surprisingly it 
was again comparable to the controls at 62 weeks (Fig. 4.5B). 
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Intrigued by the sudden increase in the S100+ cells number at 62 weeks, I decided to stain 
cerebellar slices with an antibody against the transcription factor SOX2 (Fig. 4.5A). In fact, it 
has been shown that SOX2 is expressed in neural stem and progenitor cells, glial precursors 
and proliferating astrocytes [206, 207]. I observed an increased number of SOX2+ cells in astro-
L2 KOs at 8 weeks, compared to Ctrls. This suggests that there is ongoing proliferation already 
at this age. However, at 32 weeks of age the number of SOX2+ cells is still slightly higher in 
the astro-L2 KO compared to the Ctrls, but quite reduced compared to the 8 weeks-old mice 
(Fig.4.5C). This indicates a proliferation process ongoing at early stages of the phenotype 
development that either slows down before 32 weeks or it is hardly detected because of cell 
death. However, the proliferation continued over time, as the number of SOX2+ and S100+ cells 
in astro-L2 KOs at 62 weeks were comparable to the respective Ctrls. 
In the astro-DKO line, BG marked with S100 appeared comparable to control animals at 3 
weeks, but at 4 weeks the BG appeared highly deteriorated, with short processes and cell body 
displacement towards the ML (Fig. 4.5D and G). The S100+ cell count showed the reduction in 
the number of BG cell bodies lying in the PCL at 4 weeks, but interestingly the cell loss started 
already at 3 weeks, before animals show any phenotype when compared to L1-/- (Fig. 4.5E). 
Moreover, SOX2 staining (Fig. 4.5D) nicely reflected the S100 data: at 3 weeks I could not 
detect any major difference between L1-/- and astro-DKOs, but at 4 weeks the SOX2+ cells 
appeared reduced in number (Fig.4.5F), and translocated to the ML as well (Fig. 4.5H). Overall, 
it seems that the BG phenotype in astro-DKOs develops much faster than the astro-L2 KOs. 
However, in both cases, targeted cells die. The conclusion is that astrocytes in vivo do not 
survive m-AAA protease depletion. 
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Figure 4.5: m-AAA protease depletion leads to BG premature death. (A and D) Micrographs show 
S100 and SOX2 immunofluorescence staining of cerebellar slices. n=3 for each group at each time point, 
scale bar= 20 µm. (B and E) quantification of S100+ cell bodies in the PCL. (C and F) Quantification of 
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SOX2+ cell bodies in the PCL. Dots indicate the n, data represent mean±SEM, p value was obtained 
with Student´s t-test and indicated in the graphs when ≤0.05. (G-H) Distribution of S100 and SOX2+ 
cells across the PCL and the ML. n is indicated on the bars. 
4.6 The GFAP promoter does not target NG2 precursor cells 
The sudden increase in targeted cells between 3 and 8 weeks in astro-L2 KO cerebella may be 
due to astrocyte proliferation, as most of the S100+ cells and mtYFP endogenous signal co-
localize (Fig. 4.1C). However, another possibility is that precursor cells may be targeted and 
proliferate. To test this hypothesis, I looked up for progenitors that have been reported to 
differentiate in BG. Nerve/glial antigen 2 positive cells (NG2+) count as 5-8% of the total cells 
in the CNS [208, 209]. Research conducted to identify the fate of NG2+ progenitors revealed 
that they could differentiate in both oligodendrocytes and in BG in late stages of cerebellar 
development [210]. Therefore, I stained cerebellar slices of 3 and 8 week-old astro-L2 HET 
mice expressing mtYFP with an antibody against NG2, and anti-GFP antibody that detects the 
mtYFP. I could not detect any co-localization between NG2+ cells and GFP+ cells, further 
confirming that the models I used are astrocyte-specific in the CB at 3 or 8 weeks (Fig. 4.6). 
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Figure 4.6: Targeted cells are not NG2+ precursor cells. (A-B) Immunofluorescence staining on 
cerebellar slices against NG2 and mtYFP. n=3 for each group. Scale bar= 20 µm; scale bar enlargement= 
10 µm 
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4.7 Regulation of mitochondrial functions in astrocyte-specific m-
AAA protease deficient mouse models 
4.7.1 m-AAA protease deficiency does not alter respiratory efficiency in 
targeted BG 
Due to its role in degradation of respiratory complexes subunits [146] and activation of 
MRPL32 [211], a component of the mitochondrial ribosomal machinery, m-AAA protease 
dysfunction was suspected to cause mitochondrial respiratory deficiency. Studies conducted to 
shed light onto this hypothesis showed that m-AAA protease dysfunction leads to reduced 
respiration in different cell types like neurons and oligodendrocytes [123, 146, 165, 167, 211]. 
It has been also shown that knocking out Cox10 (encoding for a subunit of complex IV) or 
Twinkle (encoding for the Twinkle helicase, important for mtDNA replication) in astrocytes 
leads to impaired mitochondrial respiration [34, 187]. However, the result of the two deletions 
is very different: Cox10-deficient cells, in fact, survive by aerobic glycolysis in absence of glial 
pathology or neurodegeneration, while Twinkle-deficient astrocytes induce spongiotic 
degeneration of brain parenchyma, secondary neuronal degeneration and microgliosis. Thus, to 
test the effect of m-AAA dysfunction in mitochondrial respiratory capability in astrocytes, I 
performed the COX-SDH staining of cerebellar slices from both astro-L2 KOs and astro-DKOs 
(and their relative controls) at different time points. This histochemical technique allows to 
check for respiratory dysfunction due to mtDNA impairment [212]. The enzymes tested with 
this method are usually the succinate dehydrogenase (SDH), which is entirely encoded by 
nuclear DNA, and the cytochrome c oxidase (COX), which is partially encoded by mtDNA. In 
case of defective mtDNA transcription or mitochondrial translation impairment, COX does not 
function, whereas the SDH carries out its activity. In healthy conditions, the COX substrate 
diaminobenzidine (DAB) is converted to brown indamine that deposits inside mitochondria. 
The SDH substrate nitroblue tetrazolium (NBT), on the other hand, is converted to blue 
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formazan. In case of respiratory deficiency caused by impaired mtDNA transcription or 
translation, mitochondria appear blue, because the COX lacks its mitochondrial encoded 
subunits to properly function [212]. Previous reports showed that Afg3l2-depleted neurons have 
COX deficiency and, therefore, impaired mitochondrial respiration [165]. Moreover, m-AAA 
protease impairment is also associated with decreased mitochondrial translation and respiratory 
chain assembly [140, 146, 165, 211]. 
The COX-SDH staining on cerebellar slices of both astro-L2 KOs and astro-DKO, surprisingly, 
did not reveal any respiratory impairment in BG cells (Fig. 4.7A and B). This interesting result 
demarks a separation between the m-AAA protease dysfunction in astrocytes and respiratory 
efficiency.  
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Figure 4.7: m-AAA protease ablation does not cause respiratory deficiency in astrocytes. (A-B) 
COX-SDH staining on cerebellar slices show no signs of COX deficiency at any time point analyzed 
in both astro-DKO and astro-L2 KO mice. n=3 for each group at each time point, scale bar= 100 µm. 
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4.7.2 m-AAA protease ablation induces metabolic stress response 
Mitochondrial stress response is common in mitochondrial diseases [213]. It has been shown 
that in case of mtDNA replication defects, deoxynucleotyde (dNTP) pools could be insufficient 
and/or unbalanced. This, rather than oxidative phosphorylation defects, leads to the integrated 
mitochondrial stress response which results in upregulation of the regulatory enzyme of the 
one-carbon folate cycle, the methylene-tetrahydrofolate dehydrogenase 2 (MTHFD2) and de 
novo serine and glutathione synthesis induction [214]. Upstream of the MTHFD2 activation is 
the induction of the mechanistic target of rapamycin 1 (mTORC1), connecting metabolic 
response and cell growth pathways [213, 215]. To verify whether the mitochondrial stress 
response is induced, I tested if enzymes involved in serine biosynthesis, the phosphoglycerate 
dehydrogenase (PHGDH) and phosphoserine aminotransferase 1 (PSAT1), and MTHFD2 were 
upregulated in astro-DKOs at 3 and 4 weeks. I focused on the astro-DKO line as it develops a 
strong and early-onset phenotype. Indeed, quantitative real time PCR results from total 
cerebellar RNA isolation confirmed that in astro-DKOs at 3 weeks the integrated stress 
response is induced, and it worsen at 4 weeks (Fig. 4.8A). To further confirm the induction of 
serine biosynthesis, I checked the amino acid levels from total cerebellar lysates of 3 and 4 
weeks old astro-DKO animals (Fig. 4.8B and C) in collaboration with Dr Susanne Brodesser. I 
could detect increased amounts of several amino acids, including serine, threonine, proline and 
glycine, which were also reported to be upregulated in muscles of mice carrying a dominant 
Twinkle helicase defect, which develop mitochondrial myopathy [214].  
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Figure 4.8: Metabolic stress response is induced by m-AAA protease dysfunction in astrocytes. (A) 
mRNA levels, expressed as fold increase, of serine metabolism involved enzymes at 3 and 4 weeks in 
astro-DKOs cerebella, compared to age-matched L1-/- animals. n ≥ 2 for each group at each time point. 
(B-C) Amino acid levels in astro-DKO at 3 and 4 weeks compared to age matched L1-/-. n ≥ 3 for each 
group at each time point. Data represent mean±SD, p value obtained by Student´s t-test is reported on 
the graph when <0.05. 
4.8 Glutamate transport is affected in m-AAA protease deficient 
astrocytes 
When I checked for amino acid levels in astro-DKOs at 3 and 4 weeks, I could detect 
upregulation of those involved in mitochondrial stress response, as well as downregulation of 
glutamate and glutamine (Fig. 4.8B and C). This is in line with the evidences indicating 
astrocytes involvement in glutamate uptake and recycling [43]. In fact, glutamate is released 
from the presynaptic neurons and binds glutamate receptors on the dendrites of postsynaptic 
neurons. To avoid excitotoxicity, glutamate must stay in the synaptic cleft for a limited amount 
of time. Its removal is operated by transporters expressed on astrocyte surface EAAT1 and 2, 
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also referred to as glutamate-aspartate transporter (GLAST) and glutamate transporter 1 
(GLT1), respectively [216, 217]. Once inside astrocytes, glutamate is converted into glutamine 
by the glutamine synthetase, and shuttled to neurons for glutamate synthesis [218-220]. 
Therefore, I checked the expression of both EAAT1 and 2 in astro-L2 KOs and astro-DKOs. 
At 4 weeks of age astro-DKO mice manifest a dramatic reduction of both transporters compared 
to L1-/- (Fig. 4.9A). These data further confirm the low glutamate and glutamine levels: due to 
lack of transporters, glutamate cannot be recycled. At 3 weeks of age, however, I could not 
detect any major difference between groups for each transporters. 
Intrigued by the results on the astro-DKOs, I tested the same antibodies on the astro-L2 KOs 
(Fig. 4.9B). Surprisingly, EAAT1 levels are unaffected compared to control animals at any time 
point analyzed. EAAT2 on the other hand, appeared patchy and not uniformly distributed in the 
ML at 32 and 62 weeks, suggesting a lower expression of this glutamate transporter in BG, 
likely impairing glutamate transport. However, EAAT1 levels are unchanged, and it can 
compensate for the EAAT2 loss.  
The results obtained from the astro-L2 KO cerebella suggest that m-AAA protease dysfunction 
could differentially affect the expression of the two EAATs. 
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Figure 9: Glutamate transporters are downregulated upon m-AAA dysfunction in astrocytes. (A-
B) Immunofluorescence staining of cerebellar slices against glutamate transporters EAAT1 and 2. n=3 
for each group at each time point, scale bar= 20 µm. 
4.9 m-AAA protease deficiency causes cell autonomous reactive 
astrogliosis 
GFAP is normally used as a generic marker for astrocytes [4, 221], and it is upregulated during 
a reactive astrogliosis [12, 222]. In case of injury or neurodegeneration, reactive astrocytes 
remove debris, dead cells, phagocyte synapses and repair the blood-brain barrier. Furthermore, 
they confine the injured areas and create a scar to avoid spreading of the damage to unaffected 
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brain areas [53-55, 223]. In order to evaluate whether m-AAA protease deficiency causes 
reactive astrogliosis, I stained cerebellar slices of both mouse models with an anti-GFAP 
antibody. Interestingly, astro-L2 KO mice show a mild reactive phenotype only at 32 weeks, 
which gets resolved by 62 weeks (Fig. 4.10A). This is in line with what I observed with the 
S100+ cells counts: at 32 weeks there is a reduction of BG cells, but by 62 weeks, the number 
of BG cells is comparable to Ctrls (Fig. 4.5A and B). It could be that in this model, reactive 
astrocytes remove dead cells and proliferate to replenish the reduced pool of BG cells, and stop 
once they fulfill their duty. In astro-DKO mice, I could detect a mild reactive astrogliosis at 3 
weeks, which became more pronounced at 4 weeks (Fig. 4.10B). Again, the comparison to the 
S100+ cell counts is necessary: S100+ cells are already mildly reduced at 3 weeks, and strongly 
reduced one week later. It is possible to speculate that the degree of reactivity may depend on 
BG loss. In astro-DKOs, because cells die rather fast, it is necessary to quickly remove them. 
In addition, dying cells must be replaced, thus reactivity may be a mean to replenish the pool 
of BG. 
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Figure 4.10: m-AAA protease dysfunction in astrocytes leads to reactive astrogliosis. (A-B) 
Immunofluorescence staining of cerebellar slices against GFAP. n=3 for each group at each time point, 
scale bar= 20 µm. 
However, what is the identity of these reactive cells? An alternative hypothesis is that reactive 
astrogliosis is triggered by the mitochondrial dysfunction within the same cell, rather than being 
induced in healthy untargeted cells reacting to environmental stimuli. To discriminate the origin 
of reactive cells, I took advantage of the mtYFP reporter and stained cerebellar slices for both 
GFAP and GFP. Remarkably, most of the reactive cells in astro-L2 KOs appear to be mtYFP+ 
(Fig. 4.11A), suggesting that indeed this is a cell autonomous effect caused by the dysfunction 
of mitochondria, rather than an attempt by untargeted cells to replenish the BG pool. However, 
some untargeted cells are reactive, indicating that the reactive astrogliosis in this model is both 
cell and non-cell autonomous. Therefore both the self-reactivity and the replenishing theories 
are still applicable and need further investigation.  
In the astro-DKO model, most of the cells at 4 weeks were untargeted, but it could be due to 
the fact that at the 4 weeks time point, targeted cells are mostly dead (Fig. 4.11B).  
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Figure 4.11: Reactive astrocytes belong to both target and untargeted pools. (A-B) 
Immunofluorescence staining against mtYFP and GFAP. n=3 for each group. Scale bar= 20 µm, scale 
bar enlargement= 20 µm. 
4.10 m-AAA protease depletion causes neuroinflammation 
Considering the strong reactive astrogliosis and the cell loss observed in astro-DKO mice at 4 
weeks, it seems reasonable that microglia cells are activated. Despite the unclear dynamics, it 
seems that cytokines released by microglia can activate toxic reactive astrocytes, but it is hard 
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to discriminate the chicken and the egg, because they are activated in same situations at very 
close time [12, 63]. Therefore, I decided to test microglia activation using the ionized calcium 
binding adaptor molecule 1 (Iba1) [224], a microglia-specific calcium-binding protein 
upregulated in activated microglia (Fig. 4.12A). Microglia activation was detected at 4 weeks, 
after the first signs of reactive astrogliosis at 3 weeks (Fig. 4.10B). Moreover, TNF-α and 
interleukines are upregulated in astro-DKOs at 4 weeks, further confirming an ongoing 
inflammatory process (Fig. 4.12B). The morphology of activated microglia reminds that of 
EAAT2+ cells in astro-DKOs at 4 weeks (Fig.4.9A). To assess whether these are astrocytes or 
microglia cells expressing EAAT2, I co-stained cerebellar sections with both Iba1 and EAAT2 
markers. Interestingly, I detected a perfect co-localization between the two antibodies in astro-
DKOs at 4 weeks (Fig. 4.12C). This means that EAAT2 glutamate transporter is expressed in 
microglial cells, rather than in BG. EAAT2 expression in microglial cells has been reported 
previously. In case of neurotoxic stimuli, and incapability of astrocytes to uptake glutamate, 
microglia upregulates EAAT2 to remove the neurotransmitter from the extracellular 
environment [225, 226]. 
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Figure 4.12: Depletion of the m-AAA protease induces inflammation. (A) Immunofluorescence 
staining against microglia marker Iba1 in cerebellar slices of L1-/- and astro-DKO mice. n=3 for each 
group at each time point. (B) mRNA levels of inflammatory markers, expressed as fold increase, from 
astro-DKO cerebella, normalized to age-matched L1-/-. n≥2 for each group at each time point. Data 
represent mean±SD, p value obtained by Student´s t-test is reported on the graph when <0.05. (C) 
Immunofluorescence staining against microglia marker Iba1 and glutamate transporter EAAT2. n=3. 
Scale bars=20 µm. 
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As microglia were activated in astro-DKO mice, I wondered if it was the case also for the astro-
L2 KO mice. I stained cerebellar slices with Iba1 but I could not detect any microglial activation 
(Fig.4.13). Interestingly, these results suggest that reactive astrogliosis occurs prior to microglia 
activation. 
 
Figure 4.13: Astro-L2 KOs do not show signs of microglial activation. Immunostaining against 
microglia marker Iba1. n=3 for each group at each time point, scale bar= 20 µm.  
4.11 Astrocyte-specific m-AAA protease ablation causes 
morphological and electrophysiological abnormalities in PCs 
To establish if neurons were secondarily affected by mitochondrial dysfunction in astrocytes, I 
stained PCs with calbindin (a Ca2+ binding protein expressed in PCs) and SMI31 that targets 
parallel fibers. Astro-L2 KO animals show PCs cell bodies tightly packed one close to the other, 
at 32 and 62 weeks. In some cases, PCs cell bodies were also slightly towards the ML. 
Moreover, the dendritic tree of PCs in astro-L2KOs appears disorganized, as the primary 
branches are bent rather than straight toward the ML. I could not detect any major difference in 
the parallel fibers (Fig. 4.14A).  
In astro-DKOs the situation was different: at 3 weeks there were no differences in the 
appearance of both PCs and parallel fibers compared to the L1-/-. However, at 4 weeks, PCs 
appeared quite disrupted, with abnormal dendrites, small cell bodies that in some cases are more 
towards the ML than the PCL (Fig. 4.14B). 
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Figure 4.14: m-AAA protease dysfunction in astrocytes leads to PC morphological abnormalities. 
(A-B) Immunofluorescence stainings for PC marker calbindin and parallel fiber marker SMI31 in 
cerebellar slices of astro-L2 KOs and astro-DKOs and relative controls. n=3 for each group at each time 
point. Scale bar=20 µm. 
To further elucidate the effect on PCs in the more severe astro-DKO mouse model, I 
collaborated with Dr Simon Hess to perform electrophysiological recordings on cerebellar 
slices from animals at 4 weeks. Freshly dissected CB were cut in slices and kept in aCSF. A 
cocktail of different inhibitors of glutamatergic and GABAergic stimuli was used to abolish 
any neuronal activation induced by surrounding cells. In resting conditions, perforated patch 
clamp on PCs of L1-/- animals confirmed that these cells have a pattern of spontaneous activity 
[227, 228]. Following the recordings in resting conditions, PCs from L1-/- show a regular firing 
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pattern at 4 weeks (Fig. 4.15A, lower panel). However, this was not the case for astro-DKO 
PCs. In fact, there was almost no recording of spontaneous activity, as quantified in Fig. 4.15B. 
Following the recordings, measured cells were visualized at the microscope with biocytin-
labeling. The lower dendritic arborization of astro-DKO PCs compared to the L1-/- can be 
noticed (Fig. 4.15A, upper panel). Then, hyper-polarizing current pulses were used to evaluate 
membrane resistance. Interestingly PCs of astro-DKO mice showed a higher cell input 
resistance than the respective controls (Fig. 4.15C), suggesting ion channels changes. 
Moreover, when stimulated with electric pulses, the neuronal response was lower than in L1-/- 
, as indicated from the current-frequency plot with a shallower slope for the astro-DKOs 
compared to the L1-/-. The number of spikes was quite reduced in astro-DKOs  (Fig. 4.15D).  
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Figure 4.15: m-AAA protease dysfunction causes electrophysiological abnormalities in PCs. (A) 
Stained PCs and respective spontaneous activity ephys of L1-/- and astro-DKOs. (B) Percentage of 
spontaneously active versus silent neurons in L1-/- and astro-DKOs. The number of neurons analyzed in 
indicated in the bars. (C) Membrane resistance indicated in mega ohm (MΩ). The number of neurons 
analyzed is indicated in the bars. Data represents mean±standard deviation (SD), p value was obtained 
by Student´s t-test and is indicated when < 0.05. (D) Evaluation of excitability of PCs, expressed as 
spikes per pulse. The number of neurons analyzed is indicated in the graph. On the left side, example of 
ephys from L1-/- (upper) and astro-DKO (lower) PCs. Animals were tested at 4 weeks of age, n ≥ 3 for 
each group. 
Considering the morphological alterations in PCs caused by BG dysfunction, I decided to 
evaluate whether the synapses on PCs were also affected. Electron microscopy images were 
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acquired in random areas of the ML. I counted the active synapses, identified as areas of 
increased electron density where the membranes of pre and postsynaptic buttons were visible, 
often showing synaptic vesicles. The quantification did not show any significant difference in 
the synaptic density in astro-L2 KOs and astro-DKOs (Fig. S3 and S5C). 
 In the ML, it is possible to identify two different types of synapses occurring at the PC dendrites 
In fact, synapses between PCs and climbing fibers (axons deriving from neurons located in the 
olivary nuclei) can be identified using vesicular glutamate transporter 2 (vGlut2). Synapses 
between PCs and parallel fiber express, instead, the vesicular glutamate transporter 1 (vGlut1) 
transporter [229]. I used an antibody against vGlut2 marker on cerebellar slices, as it is easier 
to quantify because of the lower expression. While in the astro-L2 KO mouse model I could 
not detect any difference between astro-L2 KOs and Ctrls (Fig. S4), in the astro-DKOs the 
number of vGlut2 puncta are significantly increased compared to L1-/- (Fig. S5A and B). This 
could hint to an alteration in the synaptic trim operated through glial cells [230, 231]. Overall, 
mitochondrial dysfunction that targets solely astrocytes has a deep impact on PC morphology 
and electrophysiological properties. Neurons are known to be affected by astrocyte dysfunction 
[187, 232, 233]. However, this is the first time that a mitochondrial protease ablation, which is 
not causing OXPHOS deficiency, selectively removed from astrocytes causes neuronal 
degeneration. 
4.12 m-AAA protease ablation in astrocytes causes upregulation of 
necroptotic markers, but not apoptosis 
As previously discussed, targeted cells disappear over time in both KO models. According to 
the most recent theories concerning Afg3l2 deletion, it could be due to calpain-mediated cell 
death or apoptosis [138, 170]. In both hypothesis, calcium handling is abnormal, and it could 
either cause activation of calpain enzymes or being buffered excessively by mitochondria, 
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leading to MPTP opening and apoptosis induction. To shed light on this matter, I decided to 
test whether there was activation of caspase 3 (cleaved-caspase 3), one of the most used markers 
for apoptosis [234]. In both models, I could not detect an increased number of cleaved-caspase 
3+ cells while counting all the positive cells in each section analyzed (Fig. 4.16A and B). 
Focusing only on the astro-DKOs and L1-/-, as astro-DKOs manifest a stronger phenotype, I 
tried to detect calpain activation by western blot on total cerebellar lysates. Gephyrin is known 
as target of activated calpains, and it is cleaved forming a 48 kDa fragment called E-domain, 
recognized by the 3B11 antibody [235]. Gephyrin is a glycine and GABA receptors anchoring 
protein expressed in both neurons and astrocyte [236, 237]. Astro-DKOs do not show any 
increased cleavage of gephyrin, which looks comparable to the L1-/- levels (Fig.4.16C). I 
therefore excluded calpain activation as cell death in astro-DKOs. I then decided to check for 
necroptosis, a pathway that combines apoptosis and necrosis features, and apoptosis with a 
different approach: I analyzed mRNA levels of both apoptotic and necroptotic markers from 
total cerebellar extracts (Fig. 4.16D). I used different necroptosis markers reported in literature. 
Fas-associated protein with death domain (FADD) is an adaptor protein involved in caspases 
cascade activation [238]. The receptor-interacting serine/threonine protein kinases 1/3 (RIPK1 
and 3) are mediators of necroptosis [239]. The pseudokinase mixed lineage kinase domain-like 
(MLKL) has been reported to induce necroptosis following RIPK3-mediated phosphorylation 
[240]. Z-DNA binding protein 1 (ZBP1) activates RIPK3 upstream to MLKL [241]. As marker 
for apoptosis, I used the Bcl-2 homologous antagonist/killer (BAK), a pro-apoptotic regulator 
[242]; the p53 upregulated modulator of apoptosis (PUMA) [243] and myeloid cell leukemia 1 
protein (MCL1), a pro-survival regulator of apoptosis [244]. Confirming the cleaved-caspase3 
results(Fig. 4.16 B), I could not detect upregulation of apoptotic markers, except PUMA, which 
could also be involved in necroptosis [245]. On the contrary, necroptosis markers were 
upregulated, indicating ongoing necroptosis in the tissue (Fig. 4.16 D). I could also detect 
increased protein levels of RIPK3 in total cerebellar lysates, further confirming the quantitative 
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real time PCR results (Fig. 4.16E). Necroptosis markers were all highly increased. However, I 
cannot claim that necroptosis is the occurring death pathway for targeted cells. In fact, these 
markers are upregulated in activated microglia [246, 247], which is present in this mouse model, 
thus further investigation is required.  
 
Figure 4.16: m-AAA protease depletion causes upregulation of necroptotic markers. (A-B) 
Quantification of immunohistochemistry against the apoptosis marker cleaved-caspase 3. Dots represent 
the n. Data are presented as mean±SEM. (C) Western blot from total cerebellar lysates for gephyrin full 
length (target of calpain) and 3B11 (cleavage product of calpain targeting gephyrin) and pan-actin as a 
loading control. (D) mRNA level of necroptotic and apoptotic markers, expressed as fold increase to the 
age-matched L1-/-. n=3 for each group, data represent mean±SD, p value obtained with Student´s t-test 
is indicated when < 0.05. (E) Western blot against RIPK3 (necroptotic marker) which is upregulated in 
astro-DKOs at 4 weeks.	
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5 DISCUSSION 
5.1 Conditional KO mouse models as a tool for understanding the 
contribution of glial cells to neurodegeneration 
The pleiotropic functions of the m-AAA protease give it an important role within mitochondrial 
homeostasis. In fact, due to the range of targets, its function is directly or indirectly correlated 
with many mitochondrial processes such as translation, mtDNA maintenance, respiration, 
fusion-fission balance, mitophagy and protein quality control [114, 119, 133, 134, 139]. m-
AAA protease dysfunction leads to mitochondrial impairment and neuronal death, and in 
humans it is associated with different neurodegenerative diseases, with a different neuronal 
target depending on the mutated subunit [114, 123, 133, 156, 211]. Interestingly, the focus of 
researchers has been understanding the mechanisms leading to neuronal death, as all the 
diseases caused by m-AAA protease dysfunctions are considered neuronal-diseases. Indeed, a 
PC-specific Afg3l2-KO mouse model showed that PCs die within few weeks, reinforcing the 
idea that neurons are highly susceptible to m-AAA protease deficiency and that they die in a 
cell-autonomous fashion [165]. However, the contribution of glial cells to neuronal welfare 
should not be underestimated. In fact, m-AAA protease ablation specifically in myelinating 
cells induces improper axonal myelination and death of targeted cells, resulting in the 
development of a motor defect [167]. Moreover, the finding by Maltecca et al., [170] that 
reducing synaptic stimulation of PCs actually ameliorates the phenotype of a SCA28 mouse 
model, suggests an important contribution of glial cells in the development of the phenotype. 
Indeed, the group showed that induction of EAAT2 expression in astrocytes with ceftriaxone 
treatment improves the ataxic symptoms. In addition, the contribution of glial cells in the 
development of neurodegenerative diseases has recently been taken under consideration. Beside 
that there are neurodegenerative diseases caused by glial cells dysfunction, such as the 
Alexander disease [66, 67], the use of conditional mouse models have shed some light on the 
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contribution of glial cells to the development of neurodegeneration. Ignatenko et al., [187] 
recently showed, by the means of conditional Twinkle helicase KO in neurons or astrocytes, 
that mtDNA loss in neurons leads to a sudden neurodegeneration between 7 and 8 months. 
However, mtDNA loss specifically in astrocytes leads to a much earlier phenotype 
development, which includes also spongiosis, a symptom observed in patients affected by 
mitochondrial encephalopathies such as Alpers–Huttenlocher and Leigh syndrome. Moreover, 
different mouse models in which Parkinson disease related genes were knocked out in 
astrocytes, showed the incapability of astrocytes to promote dopaminergic neuron survival, 
causing also the development of motor impairment [248]. In my work, I could indeed detect 
that Afg3l2-KO or m-AAA protease ablation in astrocytes is sufficient to induce motor 
impairment development. My findings suggest that mitochondrial dysfunction impairs 
astrocytic functions, such as glutamate recycling, without causing respiratory deficiency. 
Uncoupling mitochondrial respiration from other mitochondrial functions is extremely 
important. In fact, Supplie and colleagues [34] showed that respiratory deficiency in astrocytes 
has no detectable effect in cellular viability, and does not cause any secondary phenotype on 
neurons or motor impairment in the mouse model. In my thesis, I described the effect of m-
AAA protease dysfunction in astrocytes, which causes mild or severe phenotype on animals in 
a dose-dependent manner, without inducing any detectable respiratory deficiency (Fig. 4.7). 
The results obtained during my thesis show that not only m-AAA protease impairment in 
astrocytes leads to cell demise, but also alters PCs morphology and electrophysiological 
properties, causing a reduced arborization of the dendritic tree, as well as reduced excitability. 
Moreover, neuroinflammation was detected. The data collected in this work suggest a relevant 
contribution of astrocytes in the development and progression of SCA28 and SPAX5. 
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5.2 Gender-specific phenotype delay 
As AFG3L2 gene is located at chromosome 18 in humans [155], both SCA28 and SPAX5 
follow the autosomal inheritance mode. However, as only few families have been reported to 
develop SCA28, and even less SPAX5, it is not yet possible to establish either penetrance or 
gender effects [249]. Until now, no gender-related peculiarities have been reported. In line with 
the theoretical equality due to autosomal transmission, male and female astro-DKOs do not 
show any prominent difference in neither the motor impairment nor the cerebellar phenotype. 
On the contrary, astro-L2 KO mice manifested gender-specific differences: despite both groups 
appear to be smaller compared to the relative gender and age-matched controls, astro-L2 KO 
males have a lower rotarod latency to fall compared to Ctrls starting at 32 weeks of age, whereas 
females may have a tendency towards worse performance at 62 weeks. This finding suggests 
that females develop the phenotype at a slower pace. Indeed, it was shown that primary 
astrocyte cultures from female pup brains proliferate in presence of steroid hormones 
progesterone and estrogen. These hormones have also the effect of inducing fusion and fission 
events, therefore affecting mitochondrial dynamics [250]. The same effect was not observed in 
primary astrocyte cultures obtained from male pups: there was no increased proliferation when 
treated with estrogen. Moreover, progesterone treatment reduced the total cell number. In 
addition, the two hormones in male-astrocytes culture differentially affected mitochondrial 
dynamics: estrogen increased the transcription of fusion/fission genes, whereas progesterone 
decreased it.  
Tamoxifen, used to induce the Cre recombinase translocation to the nucleus, is an estrogen 
receptor-binding drug. Its effect on endogenous estrogen receptors has been studied and gender 
differences have been reported especially in kidney diseases, where tamoxifen-inducible CreER 
systems could give confounding results [251]. However, gender differences are attributed 
mostly to the promoter used for targeting the recombination to specific subsets of cells, and to 
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the gene under study [251, 252]. Concerning the AFG3L2 protein-associated phenotypes, no 
gender-related differences have been reported so far, nor in human nor in mouse models. It was 
shown that astrocytes reactivity varies in a sex- and estrous-cycle dependent manner in adult 
animals with brain injuries, and also in primary culture [253, 254]. However, no sex differences 
related to the GFAP promoter were reported. Therefore, I excluded a tamoxifen- or promoter-
related gender difference in astro-L2 KOs.  Indeed, the hypothesis that sex hormones can protect 
astrocytes with mitochondrial dysfunction is intriguing and would need further investigation. 
5.3 Mitochondrial morphology, phenotype development and cell 
death 
Mitochondrial morphology is altered in case of m-AAA protease dysfunction [152, 165, 167]. 
It has been shown that m-AAA protease dysfunction leads to hyper-activation of OMA1, which 
in turn processes OPA1. The increased ratio of short OPA1 isoforms over the long OPA1 
isoforms is correlated with the increased fragmentation observed in m-AAA protease deficient 
cells [116, 118, 255]. In both mouse models analyzed in this thesis, mitochondria indeed show 
fragmentation, as observed by the means of mitochondrial reporter lines. Therefore, the findings 
here reported are in line with the current available literature. An interesting observation is that 
mitochondrial fragmentation occurs already around 3 weeks in the astro-L2 KO mouse line. 
However, the motor impairment is detected not earlier than 32 weeks and also the 
morphological alterations observed in male animals lacking AFG3L2 in astrocytes, such as BG 
translocation and decreased number and PCs cell bodies almost overlapping, do not develop at 
an early stage, as at 8 weeks the CB morphology look indistinguishable from Ctrls. Therefore, 
it is likely that the slow phenotype development is due to an accumulation of dysfunctions. In 
the astro-DKO mice on the other end, the m-AAA protease ablation leads to a sudden death of 
targeted cells which results in the fast development of an ataxic phenotype. Mitochondrial 
fragmentation is already visible at 3 weeks, but the motor phenotype cannot be evaluated at this 
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age, as the cerebellar development is not yet completed and the results obtained could be 
wrongly interpreted. By visual inspection, L1-/- and astro-DKOs look indistinguishable at 3 
weeks. 
In all m-AAA protease deficient models, mitochondria not only look fragmented, but the cristae 
morphology is completely disrupted. It was reported that OPA1 can regulate the cristae 
morphology and, at the same time, preserve cytochrome c inside the cristae. OPA1 cleavage 
can open the tight junction that allow the cristae structure, resulting in release of cytochrome c  
and induction of apoptosis [95, 256-258]. Another possible way how m-AAA protease 
dysfunction could affect cristae morphology is through the accumulation of Ca2+ ions within 
the mitochondrial matrix. This would cause MPTP opening, inducing the collapse of the proton 
gradient and therefore, the dysfunction of the ATP synthesis. The resulting dissipation of the 
ionic gradient would lead to the swelling of the cristae [139]. Induction of apoptosis seems 
plausible. However, apoptosis is not induced in either the astro-L2 KO or the astro-DKO mouse 
models. In fact, mice lacking only AFG3L2 in astrocytes showed fragmented mitochondria as 
early as at 3 weeks. At 8 weeks BG cells contain mitochondria with highly disrupted cristae, 
but S100+ and SOX2+ cells counts failed to reveal cell death at this stage. Moreover, there was 
no difference in the number of cleaved-caspase 3+ cells at 8 weeks nor later at 32 weeks in the 
astro-L2 KOs. What about the astro-DKOs? The phenotype in this mouse model develops much 
faster and targeted cells die in few days. However, the cleaved-caspase 3 marker did not show 
increase at any age analyzed, and real-time quantitative PCR did not reveal upregulation of 
apoptotic markers.  
Another mechanism proposed by Maltecca et al., [168-170] consists in the activation of calpain, 
due to increased Ca2+ influx in the cytosol that would induce calpain-mediated dark cell 
degeneration in PCs in a SCA28 mouse model. Dark degenerating axons were observed also in 
the spinal cord of mice lacking the m-AAA protease specifically in oligodendrocytes [167]. In 
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neither of the mouse models studied in this work, dark cell degeneration was observed in the 
cerebellum. To conclusively exclude the calpain activation, I tested whether the calpain target 
gephyrin, an anchoring protein for glycine receptors to the cellular membrane of neurons and 
astrocytes [236, 237], was processed in cerebellar total lysates of astro-DKO mice. If the 
cleavage occurred, it would be possible to detect both a reduction of the full length gephyrin 
and the increased amount of the fragment 3B11. This was not the case and therefore I excluded 
the calpain activation. Necrotic events were not detected either and I decided to test for 
necroptosis markers upregulation in total cerebellar RNA extracts via real time quantitative 
PCR. Here, I could detect an upregulation of the necroptosis markers at 4 weeks. However, I 
cannot conclude that necroptosis is the mechanism by which targeted cells die. In fact, at the 
same time, activated microglia have invaded the cerebellum. It has been reported that reactive 
microglia upregulate necroptotic markers and could also induce necroptosis in reactive 
astrocytes, rather than being the m-AAA protease deficiency the direct cause of the necroptotic 
death [246, 247].  
A possible way to address which cells are upregulating necroptotic markers is 
immunofluorescence co-staining against necroptosis markers and astrocytes/microglia markers. 
Another method would be testing isolated astrocytes from affected animals or primary 
astrocytes, in which the deletion is induced, using western blotting techniques. However, it 
could be that once astrocytes are isolated, and not exposed to the extremely dynamic 
environment that they must monitor, they do not show the same reactivity and death. Another 
interesting method would be crossing the mouse models presented in this thesis with RIP3-
deficient mice [259] and evaluate targeted cells death.  
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5.4 Mitochondrial dysfunction and BG response 
I could successfully induce the Cre recombinase specifically in astrocytes, and BG cells showed 
a high rate of recombination. As members of the tripartite synapse with parallel fibers and PCs, 
BG proper function is crucial for synaptic transmission. Astrocytes have a quite dynamic 
mitochondrial network which is highly sensitive to neuronal activity [185]. In the m-AAA 
protease deficient mouse models, it is possible to notice mitochondrial retraction from the upper 
extremity of the ML, compared to the respective controls. It could be that dysfunctional 
mitochondria are targeted for elimination, as the morphology of BG analyzed using the S100 
marker does not appear disrupted in the early stages (3 weeks for the astro-DKOs and 8 weeks 
for the astro-L2 KOs). Possible way to test mitophagy would be performing an 
immunofluorescence staining against mitophagy or autophagy markers, such as LC3, an 
autophagosome associated protein, and to quantify co-localization with mtYFP. In vitro studies 
using autophagy blockers could also reveal if fragmented mitochondria are targeted for 
mitophagy. 
Despite mitochondrial fragmentation has been reported as an astrocytic physiological response 
to glutamate stimulation [185], I observed that following mitochondrial retraction also the BG 
projections were retracted. Moreover, I observed also that targeted cells expressing the mtYFP 
were reduced in astro-L2 KOs at 32 weeks and astro-DKOs at 4 weeks. Therefore, I can 
conclude that, comparable to neurons and oligodendrocytes, m-AAA protease dysfunction is 
not compatible with long term survival of BG. Aberrant BG projections and reduced BG 
number coincide with the motor impairment development in both mouse models, even if I 
cannot directly link temporally in a cause-effect fashion the two events.  
Despite the m-AAA dysfunction in this cell type, BG mitochondria do not show OXPHOS 
deficiency. In fact, COX-SDH staining did not reveal any respiration defect, even if 
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mitochondrial morphology is quite disrupted. Moreover, it was shown that astrocyte-specific 
KO of Cox10 does impair mitochondrial respiration but does not cause BG demise [34]. These 
results are in line with the previous literature describing astrocytes as glycolytic cells, rather 
than cells relying on OXPHOS for energy production. However, mitochondrial dysfunction has 
been reported to be lethal for astrocytes. A recent study demonstrated that astrocyte-specific 
KO of the mitochondrial helicase Twinkle causes astrocyte death. mtDNA maintenance is 
necessary for mitochondrial function and cell survival [187]. Interestingly, despite the m-AAA 
protease is important for elimination of OXPHOS subunits and it is also important for the 
translation of mtDNA-encoded proteins, targeted cells do not present respiratory deficiency. 
However, the dysfunction is so severe that causes mitochondrial stress response and cellular 
demise.  
Metabolic stress response has been reported in other mouse model in which mtDNA 
maintenance was impaired [214, 215]. In fact, mitochondrial dysfunction affects the whole cell 
metabolism, inducing changes in the cytosolic biosynthetic pathways. Of relevance is the folate 
cycle, orchestrated between mitochondria and the cytosol: the one-carbon units formed 
constitute substrates for different biosynthetic pathways, including nucleotide synthesis and 
methylation reactions. Animals carrying a dominant Twinke defect show upregulation of 
enzymes involved in mitochondrial folate cycle such as MTHFD2. Moreover, enzymes 
responsible for serine de novo synthesis, PSAT1 and PHGDH are upregulated. Serine is the 
mitochondrial primary one-carbon donor, and is used to produce both glycine and methylene-
tetrahydrofolate. The altered folate cycle causes amino acid imbalance as well as 
deoxynucleotide triphosphate increase [214]. In the astro-DKO mice at 4 weeks, I was able to 
detect upregulation of PSAT1, PHGDH and MTHFD2. A further confirmation that this 
pathway is changed is the amino acids levels detected at both 3 and 4 weeks in the astro-DKOs. 
In fact, not only serine and glycine, but also threonine and proline are commonly upregulated 
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during metabolic stress. This is the first indication that m-AAA protease deficiency can lead to 
an overall metabolic rearrangement, therefore adding a new piece to the puzzle. 
5.5 Neuroinflammation upon m-AAA protease dysfunction in 
astrocytes 
The inflammatory response is normally mediated by immune cells. However, in the CNS, 
astrocytes have a special role as they can either direct microglia activation or being activated 
themselves by microglia signaling [57, 58]. Neuroinflammation occurs in case of injury, 
infection or neurodegenerative disorders. Release of inflammation mediators induces the 
reactive state in both cell types, which includes hypertrophy, proliferation and release of 
cytokines to recruit other neuroinflammatory macrophages. In cerebella of astro-DKOs at 4 
weeks, both activated microglia and reactive astrocytes are present. The massive death of BG 
cells could explain the activation of both cell types to eliminate debris. In astro-L2 KO mice, 
microglia activation in CB was not observed, and reactive astrogliosis was detected only at 32 
weeks, indicating that at 62 weeks the cause disappeared. Both reactive astrogliosis and 
activated microglia were observed in a mouse model in which Afg3l2 was deleted specifically 
in PCs [165]. In this model, both cell types were responding to neuronal damage. While in 
astro-DKOs most, but not all, reactive astrocytes were not targeted cells, in 32-week-old astro-
L2 KO mice targeted and non-targeted cells displayed reactivity. This interesting difference 
between the two models can be explained by the fact that most targeted cells were already dead 
in 4 week-old astro-DKO, therefore the only reactive astrocytes left were the untargeted ones. 
It would be interesting to understand the mechanism leading to activation of targeted astrocytes: 
are they responding to other cells damage or to their own dysfunction? Interestingly, at 62 
weeks the reactive astrogliosis was not detected anymore in astro-L2 KOs, most likely due to 
the disappearance of targeted cells. Concerning microglial activation in the astro-DKOs at 4 
weeks, it is mostly induced following reactive astrogliosis, as the latter was mildly present at 3 
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weeks. The release of interleukins and cytokines detected in total cerebellar RNA pools could 
explain the massive microglial activation. However, the fine dynamics of astrocytes/microglia 
interplay should be further investigated. 
Another interesting difference between the astro-L2 KOs and the astro-DKOs is the fact that 
the first ones survive to the astrocyte-specific m-AAA protease dysfunction. In particular, 
despite the death of targeted cells, at 62 weeks the cerebellum does not present major 
abnormalities, beside the BG projections abnormalities, with cells moving into the ML rather 
than staying in the PCL. BG mobilization was also observed in astro-DKOs at 4 weeks. This 
phenomenon was previously observed in patients and a mouse model for the 
leukoencephalopathy vanishing white matter (VWM) disease [205]. In the VWM, the 
displacement is caused by mutation in the gene encoding for the eukaryotic initiation factor 2B, 
an important translational regulator, and causes an increased expression of the immature 
astrocytic marker nestin, as well as GFAP. The mechanism leading to BG mobilization is not 
understood and further studies are required to properly dissect the regulation of BG 
translocation. Without a reporter line for astro-L2 KOs at 62 weeks, I could not verify if the 
translocating cells were targeted or not, but the impossibility to detect abnormal mitochondria 
in 62 weeks old astro-L2 KO animals, directed me to the hypothesis that the translocating cells 
are not targeted. This observation was also reinforced by the replenished pool of BG in the PCL 
at 62 weeks. Where are these cells coming from? Already at 8 weeks both astro-L2 KO and 
HET mice show an increased number of mtYFP positive cells, hinting towards astrocytic 
proliferation between 3 and 8 weeks. The increased proliferation in astro-L2 KOs was further 
confirmed by the transcription factor SOX2, which is upregulated in proliferating astrocytes. 
These findings allow the conclusion that both targeted and untargeted astrocytes proliferate 
already around 8 weeks, but while the deficient ones die over time, the untargeted ones replace 
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them. Maybe due to the late stage of differentiation the newly inserted BG cells cannot properly 
anchor themselves in the PCL, and move towards the ML.  
BG replenishment poses an important question: which are the progenitor cells differentiating in 
new BG cells? The mtYFP reporter line showed that targeted cells are not PCs nor granule 
neurons, and the mtYFP signal perfectly co-localizes with BG markers. However, NG2+ cells 
can give rise to both oligodendrocytes and BG cells [210]. I provided proof that NG2+ cells are 
not targeted. It was not possible to establish whether new BG cells were generated by 
proliferating BG or by precursor cells.  
5.6 Glutamate dysregulation and secondary neuronal phenotype 
development 
When analyzing the amino acid levels from total cerebellar lysates, an interesting finding was 
the downregulation of glutamine and glutamate in astro-DKOs at 4 weeks. Astrocytes are 
required for glutamate recycling [37], and mitochondria provide astrocytic glutamate 
transporters with the energy necessary for their activity, being also localized close to the EAATs 
[181]. In astro-DKOs, EAAT1 was strongly decreased, while EAAT2 signal was completely 
absent in BG cells. The residual signal was instead localized to microglia cells. It was 
previously reported that in case of EAAT2 downregulation in astrocytes, microglia cells 
upregulate the glutamate transporter expression as a survival mechanism [225, 226]. In contrast, 
in astro-L2 KOs EAAT1 signal was comparable to Ctrls at any stage observed, but EAAT2 
showed overtime a patchy distribution in the ML, which was an indication of not homogeneous 
coverage of the ML, in line with the BG altered morphology.  
The impraired glutamate uptake and recycling  per se affects neurons in astro-DKOs at 4 weeks 
causing a secondary neuronal phenotype. Glutamate mishandling by BG has been previously 
reported to cause secondary neuronal impairment. In fact, ataxin-7 polyglutamine expansion in 
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astrocytes leads to reduced expression of EAAT1 leading to neurodegeneration [260]. In 
another study, Sicot et al [261] found that, in a model of myotonic dystrophy, mutant toxic 
RNA addressed BG rather than neurons, causing EAAT2 lower expression and toxicity of PCs. 
The phenotype was ameliorated, also in this case, by ceftriaxone administration. In astro-DKO 
mice at 4 weeks, m-AAA protease dysfunction induces non-cell autonomous modifications in 
both morphology and electrophysiological intrinsic properties of PCs. In fact, PCs showed 
reduced dendritic arborization. Considering that the synaptic counts did not reveal any major 
difference between L1-/- and astro-DKO at 4 weeks, the loss of dendritic arborization seemed 
counterintuitive. However, the vGlut2 puncta counts, which mark climbing fibers synapses, 
were significantly increased. It could be that while the dendritic arborization is remodeled to 
selectively reduce the synaptic input from the GCs, climbing fibers synapse increase. The 
difference between the synaptic counts could be masked this way. What cannot be 
compensated, though, is the lack of spontaneous activity of PCs, and it could be that the 
increased climbing fibers synapses are aimed to further stimulate otherwise silent PCs. The 
increased membrane potential could be a further adaptation mechanism to overcome glutamate 
hyper-stimulation from both climbing fibers and parallel fibers. It can also indicate that ion 
channels composition remodeling occurred, making neurons less excitable and affecting the 
firing rate, even when stimulated with depolarizing currents.  
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6 CONCLUSIONS 
In conclusion, with this thesis I provided evidences that an m-AAA protease dysfunction is 
incompatible with astrocytes survival. Although the dysfunction was limited to astrocytes, both 
mouse models developed motor impairment and the severity was dose-dependent. This work 
represents a direct evidence of the BG relevance in the development of Afg3l2 deficiency-
associated motor phenotypes in mouse models. The work proposed is in line with the recent 
findings by Maltecca et al., König et al., and Patron et al., in which the authors postulated that 
excitotoxicity on PCs is involved SCA28 development [138, 139, 169, 170]. As BG 
contribution should also be taken under consideration, I propose an integrated model of the 
current pathophysiological hypothesis, where BG cells are more than passive bystanders and 
actively contribute to the development and the progression of the disease. 
In a healthy situation, GC axons release glutamate vesicles in the synaptic cleft following an 
action potential. Glutamate receptors located on the postsynaptic PC dendrites bind glutamate 
and respond to the synaptic stimulation, signaling to the deep cerebellar nuclei. Meanwhile, 
glutamate transporters located on the astrocytic surface surrounding the synapse remove the 
neurotransmitter from the synaptic cleft. Inside astrocytes, glutamate is converted to glutamine 
by the glutamine synthase and shipped to the GC, where it is converted to glutamate and used 
to fill the synaptic vesicles. 
In case of AFG3L2 dysfunction, both PCs and GCs are subjected to mitochondrial dysfunction, 
which includes respiration deficiency, reduced ATP production and Ca2+ mishandling. 
Moreover, glutamate release from GC further aggravate the Ca2+ homeostasis defect caused by 
impaired mitochondrial function in PCs. BG cells with dysfunctional AFG3L2 are not able to 
promptly remove glutamate from the synaptic cleft due to the reduction of EAATs expression 
on the cellular surface. The reduced of glutamate uptake causes further hyper-stimulation of 
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PCs, and excitotoxicity. With cell death occurring, reactive astrogliosis and microglia activation 
are induced. Neurons and BG die due to the accumulation of dysfunction and induction of cell 
death pathways.  
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Figure 5.1: Integrated model of SCA28 progression. In healthy conditions, parallel fibers 
communicate with PCs via the neurotransmitter glutamate. BG clean up the synaptic cleft via EAATs 
expressed on its surface, and fueled by mitochondria. In pathogenic conditions, BG reduced EAATs 
expression causes glutamate uptake impairment. The resulting hyper-stimulation of PCs induces 
Conclusions 
 
108 
 
excitotoxicity and mishandling of Ca2+. The lack of BG support, together with the intrinsic inability to 
properly process synaptic stimulation, lead to degeneration and cell death of both astrocytes and neurons. 
These events activate both astrocytes and microglial cells, causing neuroinflammation. 
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8 APPENDIX 
Supplementary figures. 
 
Figure S1: astro-L2 KO females show delayed cerebellar morphological changes. Mild reactive 
astrogliosis and BG displacement occurs at 62 weeks in females, a later stage compared to male coun-
terparts. n=3 for each group of female mice. Scale bar= 20 µm. 
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Figure S2: astro-L2 KO females show PCs aggregation at 62 weeks. PCs cell bodies appear  
clustered, there is no sign of inflammation.=3 for each group of female mice. Scale bar= 20 µm. 
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Figure S3: astro-L2 KOs do not have a decreased synaptic number in the ML. (A) Electromicros-
copy pictures of the cerebellar ML of astro-L2 KOs and relative controls. black arrows indicate some of 
the synapses on the pictures. Scale bar= 1 µm (B) Quantification of the synapses, normalized to 20 µm2, 
n≥3 for each group at each time point. Data represent mean±SEM, Student´s t test p≤0.05. 
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Figure S4:astro-L2 KOs do not show any alteration in the number of climbing fibers synapses. 
(A) Immunofluorescence staining for vGlut2, a marker for climbing fibers synapses. n=3 for each group 
at each time point. Scale bar= 10 µm (B) Quantification of the vGlut2 fluorescent signal, normalized to 
0.02 mm2. (C) Quantification of the synapses, normalized to 20 µm2 Data represent mean±SEM, Stu-
dent´s t test p≤0.05. 
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Figure S5:astroDKOs show increased climbing fibers synapses density, but overall unchanged 
number in total synapses. (A) Immunofluorescence staining for vGlut2, a marker for climbing fibers 
synapses. n=3 for each group at each time point. Scale bar= 10 µm (B) Quantification of the vGlut2 
fluorescent signal, normalized to 0.02 mm2. (C) Quantification of the synapses, normalized to 20 µm2 
Data represent mean±SEM, Student´s t test p≤0.05. 
. 
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